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by administering to the subject a molecule that promotes
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and/or inosital triphosphate receptors (InsP3Rs) in brain
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METHODS FOR DIAGNOSING AND
TREATING ALZHEIMER'S DISEASE (AD)
USING THE MOLECULES THAT STABILIZE
INTRACELLULAR CALCIUM (CA2 J
RELEASE

Currently, the major pathological factors known to be
involved in Alzheimer's Disease (AD) include beta amyloid
accnmulation, neurofibrillary tangles (NFTs) and synaptic
dysfunction or loss. In addition, AD is associated with other
pathological processes, including failing mitochondrial
function and oxidative stress, increased inflammatory
response, protein misfolding, altered growth factor signaling, aberrant reentry of neurons into the cell cycle, lysosomal activation, endocrine alteration, insulin resistance,
cholesterol dyshomeostasis, and calcium dysregulation.
The complexity and number of changes associated with
AD has impeded attempts to disentangle the processes
important for pathogenesis and discover a treatment of AD.
Therefore, there sill remains a need for identifYing agents or
molecules that can be used for diagnosis and/or treating AD.

RELATED APPLICATIONS
This application claims priority to U.S. Provisional Patent
Application No. 61/533,056, filed Sep. 9, 2011, the entire
content of which is hereby incorporated herein by reference
as though fully set forth here.

10

GOVERNMENT LICENSE RIGHTS
15

The subject technology was made with government support under grants AG034605, AG004542 and AG010836
awarded by National Institute on Aging. The Government
may have certain rights to this invention.

SUMMARY

20

SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Dec. 27, 2012, is named Sequence Listing
50229-0611.txt and is 1,121 bytes in size.

25

FIELD
30

The subject technology relates to methods and compositions for treating Alzheimer's disease (AD) or other cognitive disorders; it also relates to a method of diagnosing
individuals who are at risk of developing AD. More specifically, the subject technology relates to calcium releasestabilizing molecules that can reduce, inhibit or reverse
calcinm dysregulation in brain cells.

35

BACKGROUND
40

The characteristic neuropathological and molecular
lesions that correlate with dementia in Alzheimer's Disease
(AD) include the accumulation of hyper-phosphorylated and
poly-ubiquinated microtubule-associated proteins, such as
tau, resulting in the formation of neurofibrillary tangles,
dystrophic neuritis, and neuropil threads. Neuronal cytoskeletal abnormalities are associated with cerebral atrophy with
cell and fiber loss, and synaptic disconnection. Increased
amyloid-beta (A~) deposition around and within the walls of
meningeal and cortical vessels, the cortical neuropil, and
neuronal perikarya is a feature of both AD and normal aging.
Although genetic factors can predispose individuals to
develop premature and excessive cerebral deposits of A~ in
AD-type dementia, most cases are sporadic and do not
exhibit clear familial or genetic clustering. Recent exploration of biochemical, molecular, and cellular abnormalities
that precede or accompany classic AD demonstrated that cell
loss was associated with increased activation of pro-death
genes and signaling pathways, impaired energy metabolism,
mitochondrial dysfunction, chronic oxidative stress, and
cerebrovascular disease/cerebral hypoperfusion. However,
the inability to interlink these phenomena under a single
primary pathogenic mechanism resulted in the emergence
and propagation of various heavily debated theories, each of
which focused on how one particular component of AD
could trigger a cascade that contributes to the development
of all other known abnormalities.
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The subject technology is illustrated, for example, according to various aspects described below.
In some embodiments, the subject technology relates to a
method of treating Alzheimer's Disease (AD), early-stage
AD, elevated risk of AD, mild cognitive impairment (MCI),
or other forms of age-related cognitive decline in a subject
in need thereof. This method includes administering to the
subject a molecule or combination of molecules that promote calcium-release stabilization in ryanodine receptors
(RyR) and/or inosital triphosphate receptors (InsP3R) in the
brain cells of the subject. In certain embodiments, the
molecule is a polypeptide, polynucleotide, small molecule or
large molecule. In an embodiment, the molecule is a polypeptide selected from immunophilins, junctophilins or
calmodulins. In another embodiment, the polypeptide molecule is FKBP1a, FKBP1b, junctophilin 3, junctophilin 4,
calmodulin 3, a functional fragment thereof or combinations
thereof. In another embodiment, the molecule is a polynucleotide encoding a polypeptide selected from immunophilins, junctophilins or calmodulins. In another embodiment, the polynucleotide molecule is a nucleic acid
sequence encoding at least one of FKBP1a, FKBP1b, junctophilin 3, junctophilin 4, calmodulin 3, a functional fragment thereof or combinations thereof. In some embodiments, the molecule is administered orally, ophthalmically,
nasally, urogentially, rectally, dermally, or by way of injection/infusion into tissue or blood.
In some embodiments, the subject technology relates to a
method of treating Alzheimer's Disease (AD), early-stage
AD, elevated risk of AD, mild cognitive impairment (MCI),
or other forms of age-related cognitive decline (collectively
cognitive decline) in a subject in need thereof. This method
includes administering to the subject a calcium (Ca2+ )release stabilizing molecule, wherein said molecule induces
reduction, inhibition or reversal of Ca2+ dysregulation in
brain cells of the subject thereby stabilizing or reducing the
cognitive decline. In certain embodiments, the molecule is a
polypeptide, polynucleotide, small molecule or large molecule. In an embodiment, the molecule is a polypeptide
selected from immunophilins, junctophilins or calmodulins.
In another embodiment, the polypeptide molecule is
FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4, calmodulin 3, a functional fragment thereof or combinations thereof.
In another embodiment, the molecule is a polynucleotide
encoding a polypeptide selected from immunophilins, junctophilins or calmodulins. In another embodiment, the polynucleotide molecule is a nucleic acid sequence encoding at
least one of FKBP1a, FKBP1 b, junctophilin 3, junctophilin
4, calmodulin 3, a functional fragment thereof or combina-
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tions thereof. In some embodiments, the molecule is administered orally, ophthalmically, nasally, urogentially, rectally,
dermally, or by way of injection/infusion into tissue or
blood.
In some embodiments, the subject technology relates to a
method for diagnosing Alzheimer's Disease (AD), earlystage AD, elevated risk of AD or mild cognitive impairment
(MCI) in a patient. This method includes (1) obtaining a
biological sample from the patient, (2) detecting the level of
expression of one or more calcium-release stabilizing immunophilin, junctophilin and/or calmodulin genes in the biological sample from said patient, wherein differential
expression of said one or more genes in the sample as
compared to control levels of expression of said one or more
genes is indicative of Alzheimer's Disease (AD), early-stage
AD, elevated risk of AD or mild cognitive impairment
(MCI). In an embodiment, the biological sample is blood,
muscle tissue, brain tissue, peripheral nervous system, cerebrospinal fluid sample or any tissue sample exhibiting
significant concentrations of immunophilins, junctophilins
or calmodulin. In another embodiment, the patient exhibits
symptoms of Alzheimer's Disease (AD), early-stage AD,
elevated risk of AD or mild cognitive impairment (MCI) or
is being treated for Alzheimer's Disease (AD) or mild
cognitive impairment (MCI). In another embodiment, the
level of expression of one or more genes is determined by a
nucleic acid polymerization or hybridization technology. In
another embodiment, at least one of the genes whose level
of expression is being determined includes FKBP1a,
FKBP1b, junctophilin 3, junctophilin 4, calmodulin 3 or a
variant thereof. In another embodiment, the one or more
genes are differentially expressed in one or more brain
regions of the patient, said brain regions being selected from
the group consisting of hippocampal formation, entorhinal
cortex, paleocortex and neocortex. In another embodiment,
the level of expression of said one or more genes is normalized to the expression level of a housekeeping gene as a
control.
In some embodiments, the subject technology relates to a
method for diagnosing Alzheimer's Disease (AD), earlystage AD, elevated risk of AD or mild cognitive impairment
(MCI) in a patient. This method includes (1) obtaining a
biological sample from the patient, (2) detecting the level of
expression of one or more calcium-release stabilizing immunophilin, junctophilin and/or calmodulin genes in the biological sample from said patient, wherein differential
expression of said one or more genes in the sample as
compared to control levels of expression of housekeeping
genes, genes whose expressions are known not to change
with AD, or the same genes obtained from normal subjects
who do not have AD is indicative of Alzheimer's Disease
(AD), early-stage AD, elevated risk of AD or mild cognitive
impairment (MCI). In an embodiment, the biological sample
is blood, muscle tissue, brain tissue, peripheral nervous
system, cerebrospinal fluid sample or any tissue sample
exhibiting significant concentrations of immunophilins,
junctophilins or calmodulin. In another embodiment, the
patient is exhibiting symptoms of Alzheimer's Disease
(AD), early-stage AD, elevated risk of AD or mild cognitive
impairment (MCI) or is being treated for Alzheimer's Disease (AD) or mild cognitive impairment (MCI). In another
embodiment, the level of expression of one or more genes is
determined by a nucleic acid polymerization or hybridization technology. In another embodiment, at least one of the
genes whose level of expression is being determined
includes FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4,
calmodulin 3 or a variant thereof. In another embodiment,

the one or more genes are differentially expressed in one or
more brain regions of the patient, said brain regions being
selected from the group consisting of hippocampal formation, entorhinal cortex, paleocortex and neocortex. In
another embodiment, the level of expression of said one or
more genes is compared to the expression level of one or
more housekeeping genes. In another embodiment, the level
of expression of said one or more genes is compared to the
expression level of one or more genes used as control.
Additional features and advantages of the subject technology will be set forth in the description below, and in part
will be apparent from the description, or may be learned by
practice of the subject technology. The advantages of the
subject technology will be realized and attained by the
structure particularly pointed out in the written description
and claims hereof as well as the appended drawings.
It is to be understood that both the foregoing general
description and the following detailed description are exemplary and explanatory and are intended to provide further
explanation of the subject technology as claimed.
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The accompanying drawings, which are included to provide further understanding of the subject technology and are
incorporated in and constitute a part of this specification,
illustrate aspects of the subject technology and together with
the description serve to explain the principles of the subject
technology.
FIG. 1 is a bar chart depicting electrophysiological effects
of unilateral microinjection into one hippocampus of aging
rats of adena-associated viral (AAV) vector containing the
open reading frame (ORF) of the Fkbp1b gene. This microinjection resulted in overexpression of FKBP1 b mRNA and
protein (confirmed by qPCR and immunohistochemistry).
Shown are the quantitative group measures (mean+/-SEM)
of intracellular electrode recordings of membrane voltage
responses that are well-established to vary in magnitude
with the amount of calcium released by intracellular ryanodine receptors (RyRs); these voltage responses are the
amplitude of the calcium-dependent medium afterhyperpolarization (mAHP) (top panel), amplitude of the calciumdependent slow afterhyperpolarization (sAHP) (middle
panel), and duration of the calcium-dependent slow afterhyperpolarization (sAHP) (bottom panel). The data reveal
significant differences in these responses in neurons
recorded from the viral vector-injected hippocampus vs.
those recorded from the control (non-injected) hippocampus, such that the injected-side neurons exhibit a younger
phenotype (lesser magnitude). Larger amplitude AHPs
develop with aging and have been correlated with impaired
memory.
FIG. 2 shows representative examples of the membrane
voltage responses (for which the quantitative data are shown
in FIG. 1). Left Colunm: AHPs that follow an induced burst
of 4 action potentials (truncated for illustration) in 3 controlside hippocampal neurons. Right Column: AHPs that follow
an induced burst of 4 action potentials in 3 injected-side
hippocampal neurons. TheAHPs are substantially smaller in
the injected-side neurons, indicating that the overexpression
ofFKBP1 b has stabilized ryanodine receptors and decreased
release of calcium from intracellular storage sites. Y-axis:
membrane holding potential (no significant differences
between control and injected neurons); X-axis: Time (msec ).
FIG. 3 shows the AAV-ORF-mediated overexpression of
FKBP1b/12.6 validated at the protein level. In vivo direct
microinjection of AAV with Fkbp1b ORF into one hip-
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pocampus (ipsilateral-ipsi) dramatically increased FKBP1 b
expression compared to the non-injected contralateral hippocampus (contra). Note more intense immunohistochemical staining of FKBP1 b/12.6 throughout ipsilateral hippocampus (ipsi) (upper panel). More intense staining is also
shown at higher magnification in the CA stratum pyramidale
(sp) layer (middle panel) and dentate gyrus (DG) (lower
panel).
FIG. 4 shows the reversal of Spatial Water Maze Learning
Deficit in Aged Rats by Hippocampal Microinjection of
Adena-Associated Viral (AAV) Vectors Expressing
FKBP1b. Panel A is a graph of the water maze learning
performance of 3 groups of F344 rats, presented as the path
length (distance in em) traveled to find the submerged
escape platform during 12 training trials and one probe
(retention) test (Shorter path length=better learning). The
groups consisted of Aged Controls (22 mo ), Aged AAVFkbp1b injected (22 mo) and Young-Adult Controls (4 mo).
The agedAAV-Fkbp1b group received bilateral infusions of
AAV expressing the Fkbp1b open reading frame. The other
two groups received infusions of control AAV expressing
only green fluorescing protein. Rats were trained by giving
three learning trials/day over 4 days. On the fifth day a probe
test was conducted with the escape platform missing to
measure memory retention. Young Controls and AgedFkbp1 b-treated animals performed significantly better than
Aged Controls on the retention test and on the final two days
of training. Panel B is the average path length on the 3rd
training trial of the 3rd and 4th training days. The Aged
AAV-Fkbp1 b group and the Young group performed significantly better than Aged controls. (*=p<0.05'**=p<0.001).

plays a major role in unhealthy brain aging (Gant et a!., J.
Neuroscience, 31 (5): 1693-1703; February 2011).
However, the subject technology relates, in part, to an
unexpected discovery that over expression of the Fkbp1b
open reading frame (ORF) in the hippocampus of aging rats
not only counteracts Ca 2 + dyshomeostasis, but also
improves maze learning and/or memory in rats. This unexpected discovery suggests that Fkpb1 b and other Ca 2 +
release-stabilizing molecules including immunophilins such
as Fkbp1a, junctophilins such as junctophilins 3 and 4 or
clamodulins such as chalmodulin 3, as well as intraneuronal
calcium channels such as ryanodine receptors (RyRs) and/or
Inositol trisphosphate receptor (InsP3R) are novel therapeutic molecules and/or targets for interventions aimed at protection against unhealthy brain aging or Alzheimer's disease
through stabilization of Ca2 + release mechanisms in brain
cells.
Accordingly, in some embodiments, the subject technology relates to a method of treating Alzheimer's Disease
(AD), early-stage AD, elevated risk of AD, mild cognitive
impairment (MCI), or other forms of age-related cognitive
decline in a subject in need thereof, by administering to the
subject a molecule that promotes calcium-release stabilization in ryanodine receptors (RyR) and/or inosital triphosphate receptors (InsP3R) in brain cells.
In some embodiments, the subject technology relates to a
method of treating Alzheimer's Disease (AD), early-stage
AD, elevated risk of AD, mild cognitive impairment (MCI),
or other forms of age-related cognitive decline in a subject
in need thereof, comprising administering to the subject a
calcium (Ca 2 +)-release stabilizing molecule, wherein said
molecule induces reduction, inhibition or reversal of Ca 2 +
dysregulation in brain cells of the subject.
In some embodiments, the therapeutic molecule of the
subject technology includes a polypeptide, polynucleotide,
small molecule or large molecule. The polypeptide suitable
for use in this embodiment can be selected from immunophilins, junctophilins or calmodulins. More specifically, the
polypeptide is a full-length amino acid sequence of at least
one FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4,
calmodulin 3 or a functional fragment thereof. The polynucleotide suitable for use in this embodiment can be
polynucleotide encoding a polypeptide selected from immunophilins, junctophilins or calmodulins. More specifically,
the polynucleotide is a nucleic acid sequence encoding at
least one of FKBP1a, FKBP1 b, junctophilin 3, junctophilin
4, calmodulin 3 or a functional fragment thereof. In another
related embodiment, the molecule is administered orally,
ophthalmically, nasally, urogentially, rectally, dermally, or
by way of injection/infusion into tissue or blood.
In some embodiments, the subject technology relates to a
method of diagnosing Alzheimer's Disease (AD), earlystage AD, elevated risk of AD or mild cognitive impairment
(MCI) in a patient, including: detecting the level of expression of one or more calcium-release stabilizing immunophilin, junctophilin and/or calmodulin genes in a biological
sample from said patient, wherein differential expression of
said one or more genes in the sample as compared to control
levels of expression of said one or more genes, or to levels
of expression in the same patient of other control genes
known not to change with AD, is indicative of Alzheimer's
Disease (AD), early-stage AD, elevated risk of AD or mild
cognitive impairment (MCI).
Definitions:
To facilitate an understanding of the present subject
technology, a number of terms and phrases are defined
below:
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In the following detailed description, numerous specific
details are set forth to provide a full understanding of the
subject technology. It will be apparent, however, to one
ordinarily skilled in the art that the subject technology may
be practiced without some of these specific details. In other
instances, well-known structures and techniques have not
been shown in detail so as not to obscure the subject
technology.
With aging, multiple Ca2 +-associated electrophysiological processes exhibit increased magnitude in hippocampal
pyramidal neurons, including the Ca2 +-dependent slow afterhyperpolarization (sAHP), L-type voltage-gated Ca 2 + channel (L-VGCC) activity, Ca 2 +-induced Ca 2 + release (CICR)
from ryanodine receptors (RyRs), and Ca 2 + transients. This
pattern of Ca 2 + dysregulation correlates with reduced neuronal excitability/plasticity and impaired learning/memory
and has been proposed to contribute to unhealthy brain aging
and Alzheimer's disease. However, little is known about the
underlying molecular mechanisms.
The inventors have recently found that expression of the
Ca2+-stabilizing molecules, FKBP1a, FKBP1b, junctophilin 3, junctophilin 4, and calmodulin 3 decreases in hippocampus of humans with early-stage AD and that this
decrease correlates with incipient cognitive dysfunction
(Blalock eta!., J. Chemical Neuroanatomy 42:118-126; July
2011 ). They have further observed that disrupting FKBP1 b
function destabilizes Ca2 + homeostasis in hippocampal neurons and is sufficient to induce the aging phenotype of Ca 2 +
dysregulation in young animals. In their study, the inventors
found that disruption of FKBP1 b recapitulated much of the
Ca 2 +-dysregulation aging phenotype in young rat hippocampus, supporting the hypothesis that declining FKBP function
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As used herein, the term "early-stage AD" refers to
incipient Alzheimer's Disease characterized by at least some
of and in many cases all of the following signs and symptoms: recent memory is impaired; learning and retaining
new information becomes difficult. Language problems (especially with word finding), mood swings, and personality
changes develop. Patient may have progressive difficulty
with independent activities of daily living (e.g., balancing
their checkbook, finding their way around, remembering
where they put things). Abstract thinking, insight, or judgment may be impaired. Patients may respond to loss of
independence and memory with irritability, hostility, and
agitation. Functional ability may be further limited by the
following: Agnosia: Impaired ability to identifY objects
despite intact sensory function; Apraxia: Impaired ability to
do previously learned motor activities despite intact motor
function; and Aphasia: Impaired ability to comprehend or
use language. Although early-stage AD may not compromise sociability, family members may report strange behavior accompanied by emotional lability. Pathophysiologically, early-stage AD refers to the beginning stages of
amyloid ~(A ~)-protein deposit in the brain. Additional
information related to identifYing early-stage AD are provided by the American Academy of Neurology (AAN).
Early stage AD can further be described in terms of the Mini
Mental State Examination (MMSE) score (See Blalock et
a!., PNAS 101(7):2173-2178 (2004)). For example, subjects
can be categorized into the following four groups based on
MMSE score: "Control" (MMSE>25), "Incipient AD"
(MMSE=20-26), "Moderate AD" (MMSE=14-19), and
"SevereAD" (MMSE<14). Earlystage AD can further be
described as a stage prior to onset of intermediate- or
late-stage AD.
In intermediate stage AD, patients are unable to learn or
recall new information. Memory of remote events is
reduced, but not totally lost. Patients may require help with
basic activities of daily living (e.g., bathing, eating, dressing,
toileting). Personality changes may progress. Patients may
become irritable, anxious, self-centered, inflexible, or angry
more easily, or they may become more passive, with a flat
affect, depression, indecisiveness, lack of spontaneity, or
general withdrawal from social situations. Behavior disorders may develop: Patients may wander or become suddenly
and inappropriately agitated, hostile, uncooperative, or
physically aggressive. By this stage, patients have lost all
sense of time and place because they cannot effectively use
normal environmental and social cues. Patients often get
lost; they may be unable to find their own bedroom or
bathroom. They remain ambulatory but are at risk of falls or
accidents secondary to confusion. Altered sensation or perception may culminate in psychosis with hallucinations and
paranoid and persecutory delusions. Sleep patterns are often
disorganized.
In late or severe stage of AD, patients cannot walk, feed
themselves, or do any other activities of daily living; they
may become incontinent. Recent and remote memory is
completely lost. Patients may be unable to swallow. They are
at risk of malnutrition, pneumonia (especially due to aspiration), and pressure ulcers. Because they depend completely on others for care, placement in a long-term care
facility often becomes necessary. Eventually, patients
become mute.
As used herein, the term "mild cognitive impairment
(MCI)" takes its ordinary meaning in the art. MCI mostly
refers to a condition that is more severe than age-associated
memory impairment. In MCI, memory is impaired compared with that of age-matched controls, but other cognitive

domains and daily function are not affected. Up to 50% of
patients with mild cognitive impairment develop dementia
within 3 yr. Normally, patients with MCI once identified are
monitored for progression to AD. MCI is an intermediate
stage between the expected cognitive decline of normal
aging and the more serious decline of dementia. It can
involve problems with memory, language, thinking and
judgment that are greater than normal age-related changes.
Patients with mild cognitive impairment may be aware that
their memory or mental function has "slipped." Their families and close friends also may notice a change. But generally these changes aren't severe enough to interfere with the
patients' day-to-day life and usual activities.
As used herein, the term "elevated risk of AD" refers to
situations where a patient suffers from MCI or shows one or
more of the 10 warning signs of AD (according to the
American Academy of Neurology guidelines on dementia,
and the Alzheimer's Association. These 10 warning signs
are: 1. Memory loss that affects job skills; 2. Difficulty
performing familiar tasks; 3. Problems with language; 4.
Disorientation to time and place; 5. Poor or decreased
judgment; 6. Problems with abstract thinking; 7. Misplacing
things; 8. Changes in mood or behavior; 9. Changes in
personality; 10. Loss of initiative. Also, it is known that
there is a familial pattern of AD, thus first-degree biological
relatives of individuals with AD may be at an elevated risk
of AD than the general population.
As used herein, a "subject" is preferably a mammal and
more preferably a hnman, but can be any animal, including
a laboratory animal in the context of a clinical trial or
screening or activity experiment. Thus, as can be readily
appreciated by one of ordinary skill in the art, the methods
of the subject technology are particularly suited to administration to any animal, particularly a mammal, and including, but not limited to domestic animals, wild animals and
research animals.
As used herein, the term "inhibit" means preventing or
delaying the onset or progression of one or more clinical
symptoms of AD. Common early symptoms of Alzheimer's
include confusion, disturbances in short-term memory, problems with attention and spatial orientation, personality
changes, language difficulties, unexplained mood swings.
The term "therapeutically effective amount" is used
herein to mean an amount or dose of a molecule of the
subject technology that is effective to ameliorate, delay, or
prevent any of the foregoing symptoms, behaviors or events
associated with Alzheimer's disease or related neurodegenerative disorders including MCI. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the individual.
As used herein, the phrase "pharmaceutically acceptable"
refers to molecular entities and compositions that are "generally regarded as "safe," e.g., that are physiologically
tolerable and do not typically produce an allergic or similar
untoward reaction, such as gastric upset, dizziness and the
like, when administered to a human. Preferably, as used
herein, the term "pharmaceutically acceptable" means
approved by a regulatory agency of the Federal or a state
government of listed in the U.S. Pharmacopeia or other
generally recognized pharmacopeia for use in animals, and
more particularly in humans.
The term "treat" is used herein to mean to relieve or
alleviate at least one symptom of a disease in a subject. As
used herein, the term "treat" also denotes to arrest, delay the
onset (i.e., the period prior to clinical manifestation of a
disease) and/or reduce the risk of developing or worsening
a disease.
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The term "promote" as used herein means to have any
positive effect or benefit. As used, the term is relative and
does not necessarily mean to enhance or improve. For
example, a molecule of the subject technology that stabilizes
calcium release (as measured electrophysiologically) in
ryanodine receptors (RyR) and/or inosital triphosphate
receptors (InsP3R) of neurons and/or muscle cells by at least
5% as compared to control cells not receiving such molecule
could still be deemed as having a promoting effect.
The terms "reference" or "control" as used herein in
relation to an expression profile refers to a normalized
pattern of gene or gene product expression or levels of
expression of certain biomarkers to be used to compare the
level of expression of the targets (e.g., FKBP1a, FKBP1b,
junctophilin 3, junctophilin 4, calmodulin 3 or a variant
thereof) of the subject technology to for the purpose of
interpreting the expression data obtained from a patient and
assigning the patient a prognostic or predictive class such as,
for example, no AD, at risk of AD, elevated risk of AD or
AD. These biomarkers can be housekeeping genes or proteins whose expressions remain unaffected by AD or clinical
symptoms of AD or MCI. The biomarkers can also be those
obtained from one or more healthy individuals known not to
have AD or clinical symptoms of AD. The biomarkers can
also be those obtained from a universal control sample
obtained by pooling a statistically significant number of
mRNAs or cDNAs from biological samples (e.g., hippocampal cells or tissues) of healthy individuals known to not have
clinical symptoms of AD or MCI.
The terms "about" and "approximately" shall generally
mean an acceptable degree of error or variation for the
quantity measured given the nature or precision of the
measurements. Typical, exemplary degrees of error or variation are within 20 percent (% ), preferably within 10%, and
more preferably within 5% of a given value or range of
values. For biological systems, the term "about" refers to an
acceptable standard deviation of error, preferably not more
than 2-fold of a give value. Numerical quantities given
herein are approximate unless stated otherwise, meaning
that the term "about" or "approximately" can be inferred
when not expressly stated.
The term "differential expression" refers to both quantitative as well as qualitative differences in the temporal and
tissue expression patterns of a gene. For example, a differentially expressed gene may have its expression activated or
completely inactivated in normal versus disease conditions.
Such a qualitatively regulated gene may exhibit an expression pattern within a given tissue or cell type that is
detectable in either control or disease conditions, but is not
detectable in both.
The term "polypeptide" includes a compound of two or
more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In
another embodiment, the subunit may be linked by other
bonds, e.g., ester, ether, etc. As used herein the term "amino
acid" includes either natural and/or unnatural or synthetic
amino acids, including glycine and both the D or L optical
isomers, and amino acid analogs and peptidomimetics. A
peptide of three or more amino acids is commonly referred
to as an oligopeptide. Peptide chains of greater than three or
more amino acids are referred to as a polypeptide or a
protein.
"Hybridization" includes a reaction in which one or more
polynucleotides react to form a complex that is stabilized via
hydrogen bonding between the bases of the nucleotide
residues. The hydrogen bonding may occur by Watson-Crick
base pairing, Hoogstein binding, or in any other sequence-

specific manner. The complex may comprise two strands
forming a duplex structure, three or more strands forming a
multi-stranded complex, a single self-hybridizing strand, or
any combination of these. A hybridization reaction may
constitute a step in a more extensive process, such as the
initiation of a PCR reaction, or the enzymatic cleavage of a
polynucleotide by a ribozyme.
Hybridization reactions can be performed under conditions of different "stringency". The stringency of a hybridization reaction includes the difficulty with which any two
nucleic acid molecules will hybridize to one another. Under
stringent conditions, nucleic acid molecules sharing at least
60%, 65%, 70%, 75% identity to each other (throughout the
entire sequence) remain hybridized to each other, whereas
molecules with low percent identity cannot remain hybridized. A preferred, non-limiting example of highly stringent
hybridization conditions are hybridization in 6x sodium
chloride/sodium citrate (SSC) at about 45° C., followed by
one or more washes in 0.2xSSC, 0.1% SDS at 50° C.,
preferably at 55° C., more preferably at 60° C., and even
more preferably at 65° C.
As used herein the term "target" refers to the polypeptides
and polynucleotides of the subject technology including
immunophilins, junctophilins, calmodulins (whose function
is to stabilize calcium release from calcium channels RyR
and InsP3R), ryanodine receptors (RyRs) and inosital
triphosphate receptors (InsP3Rs). Exemplary immunophilins, junctophilins or calmodulins are Fkbp 1a; Fkbp 1b variant (a); Fkbp1b variant (b); Junctophilin 3; Junctophilin 4,
Calmodulin 3. The modulation of quantity or activity of the
target can result in inhibition, prevention, amelioration,
treatment or reduction in the aging phenotype of Ca 2 +
dysregulation in a subject with AD, MCI or other cognitive
impairments. The cDNAand protein sequences of the exemplary targets of the subject technology can be obtained from
the National Center for Biotechnology Information (NCBI)
databases using the accession numbers listed in table below.
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NM_000801.4
NM_004116.3
NM_054033.2
NM_020655.2
NM_001146028.1

eDNA: NM_005184.2

Protein Accession No.
Protein: NP 000792.1
Protein: NP 004107.1
Protein: NP _473374.1
Protein: NP 065706.2
Protein:
NP 001139500.1
Protein: NP 005175.2

As used herein, the term "panel of targets" includes a
group of targets, the quantity or activity of each member of
which is correlated with the incidence or risk of incidence of
AD or other cognitive impairments. In certain embodiments,
a panel of targets may include only those targets which are
either increased or decreased in quantity or activity in
subjects afflicted with or cells involved in AD or other
cognitive impairments. In other embodiments, a panel of
targets may include only those targets present in a specific
tissue type which are correlated with the incidence or risk of
incidence of AD or other cognitive impairments.
As used herein, the term "small molecule" refers to a
non-peptidic, non-oligomeric organic compound either synthesized in the laboratory or found in nature. Small molecules, as used herein, can refer to compounds that are
"natural product-like", however, the term "small molecule"
is not limited to "natural product-like" compounds. Rather,
a small molecule is typically characterized in that it contains
several carbon-carbon bonds, and has a molecular weight of
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less than 2000 g/mol, preferably less than 1500 g/mol,
although this characterization is not intended to be limiting
for the purposes of the subject technology. Small molecules
are typically characterized by multiple carbon-carbon bonds
and may have one or more stereocenters. Examples of
"small molecules" that occur in nature include, but are not
limited to, taxol, dynemicin, rapamycin or JTV519 (K201).
Examples of "small molecules" that are synthesized in the
laboratory include, but are not limited to, compounds
described by Tan et a!. ("Stereoselective Synthesis of over
Two Million Compounds Having Structural Features Both
Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays" J. Am. Chern. Soc. 120:8565,
1998; incorporated herein by reference). In certain other
preferred embodiments, natural-product-like small molecules are utilized. In certain embodiments, the small molecule is not polymeric or oligomeric. In certain embodiments, the small molecule is not a nucleic acid, protein, or
peptide.
As used herein, the term large molecule refers to a drug
having a molecular weight higher than about 2000 g/mol.
Exemplary large molecules include synthetic polymers or
macromolecules with equal to or grater 2000 g/mol of
molecular weight. In certain embodiments, the large molecule is not a nucleic acid, protein, or peptide.
Previously, it was established that several classes of
molecules, including immunophilins, junctophilins, and
calmodulin 3 (CALM3) play a necessary role in stabilizing
Ca 2 + release from intracellular stores such as RyRs in
muscle and cardiac cells.
In previous studies conducted in the inventors' lab, it was
shown that the expression of the FKBPlb gene, which
encodes the FK-506 binding protein lb (FKBPlb, aka
FKBP12.6), is decreased in hippocampal cells of patients
with early-stage AD (Blalock et a!., Proc. Nat!. Acad. Sci.
U.S.A. 101:2173-2178 (2004)) and in aging rats (Kadish et
a!., J. Neurosci., 29:1805-1816 (2009)). Because the study
was conducted on hand-dissected frozen hippocampal CAl
blocks containing both white and gray matter, the authors
found that it was not possible to distinguish transcriptional
changes. Further, since heterogeneous cells types/regions
were mixed together in these studies, tissue-specific changes
were obscured. No definitive conclusion on the role of
FKBPl b in cognition and AD could be drawn or suggested.
In a more recent study (Blalock et a!, 2011 ), a gene
expression profiling of the laser-captured gray matter
regions of hippocampal sections revealed that, with AD,
brain (hippocampal) expression also decreases for a plurality
of genes that encode proteins that stabilize Ca 2 + release from
RyRs in muscle cells, including FKBPlb, FKBPla, two
junctophilins and CALM3. Further, it was found that the
decreased expression of these molecules correlated with
decreased cognitive function in early-stage AD patients.
In another more recent study (Gant et a!., 2011 ), it was
shown that directly manipulating FKBPl b in key brain
regions of rats, by microinjecting an inactivated viral vector
containing short interfering RNA against Fkbplb, can
induce Ca 2 + dysregulation (measured electrophysiologically) related to memory loss and aging phenotype.
Although the inventors' recent studies established a link
between the down-regulation or disruption of genes that
encode Ca2 + release-stabilizing molecules and the Ca 2 +
dysregulation or decreased cognitive function in early-stage
AD patients, it was unexpected to discover, as shown herein,
that microinjection of viral vector bearing the open reading
frame (orf) of one of the above genes, i.e., the FKBPl b gene,
into the hippocampus of rats results in overexpression of

FKBPlb in regions critical for memory (hippocampus) and
stabilizes Ca 2 + release. It was even more unexpected to
discover that this reversal of Ca2 + dysregulation resulted in
an improved memory. Thus, according to the subject technology, the stabilization of Ca 2 + release from the calcium
receptors such as RyRs or InsP3R, as observed in the present
disclosure, leads to the reversal of Ca2 + dysregulation and
indicates that both the receptors and molecules that stabilize
these receptors can be used as targets for developing diagnostic and/or therapeutic means for treating or inhibiting
memory loss, AD, MCI, and other cognitive or memory
impairments.
Ryanodine receptors (RyRs) form a class of intracellular
calcium channels in various forms of excitable animal tissue
like muscles and neurons. It is the major cellular mediator of
calcium-induced calcium release (CICR) in animal cells.
There are multiple isoforms of ryanodine receptors including: RyRl (Entrez ID No. 6261; Hugo ID. No. 10483; Omim
ID. No. 180901; RefSeq ID No. NM_000540; and UniProt
ID No. P21817); RyR2 (Entrez ID No. 6262; Hugo ID. No.
10484; OmimiD. No.180902; RefSeqiDNo. NM_001035;
and UniProt ID No. Q92736); and RyR3 (Entrez ID No.
6263; Hugo ID. No. 10485; Omim ID. No. 180903; RefSeq
ID No. NM_001036; and UniProt ID No. Q15413) which is
expressed more widely, but especially in the brain.
Inositol trisphosphate receptor (InsP3R) is a membrane
glycoprotein complex acting as Ca2 + channel activated by
inositol trisphosphate (InsP3). InsP3R is very diverse among
organisms, and is necessary for the control of cellular and
physiological processes including cell division, cell proliferation, apoptosis, fertilization, development, behavior,
learning and memory. Inositol triphosphate receptor represents a dominant second messenger leading to the release of
Ca 2 + from intracellular store sites. There is evidence suggesting that InsP3R plays an important role in the conversion of external stimuli to intracellular Ca 2 + signals characterized by complex patterns relative to both space and time,
for example, Ca 2 + waves and oscillations. The InsP3 receptor was first purified from rat cerebellum. There are multiple
isoforms of ryanodine receptors including: InsP3Rl (also
abbreviated as ITPRl; Entrez ID No. 3708; Hugo ID. No.
6180; Omim ID. No. 147265; RefSeq ID No. NM_002222;
and UniProt ID No. Q14643); InsP3R2 (also abbreviated as
ITPR2; Entrez ID No. 3709; Omim ID. No. 600144; RefSeq
ID No. NM_002223; and UniProt ID No. Q14571); and
InsP3R3 (also abbreviated as ITPR3; Entrez ID No. 3710;
Hugo ID. No. 6182; Omim ID. No. 147267; RefSeq ID No.
NM_002224; and UniProt ID No. Q14573).
In one embodiment, the subject technology provides a
method for diagnosing AD, early-stage AD, mild cognitive
impairment (MCI) or elevated risk of AD, comprising taking
a biopsy sample from muscle tissue or any other tissue
exhibiting significant concentrations of immunophilins,
junctophilins or calmodulin3, measuring in that sample
RNA expression (content, e.g., by qPCR, microarrays or
newer methods) for a plurality of genes that encode Ca 2 +
release-stabilizing molecules (those noted above), also measuring in the same sample RNA content for a number of
genes that do not change in brain or muscle with AD, and
comparing the ratio of expression of Ca2 + release-stabilizing
genes to expression of AD-insensitive genes, relative to a
normalizing/scaling factor (e.g., average signal of all genes)
in the same sample. Alternatively, the ratio of Ca2 + stabilizing genes could be compared to values for those same
Ca 2 + stabilizing genes in normal subjects, which would be
obtained by averaging across a statistically significant number of control subjects that did not exhibit AD or cognitive
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decline. Several statistical techniques well-known in the
field will allow determination of the degree of deviation of
the expression of Ca 2 + release-stabilizing genes from
expression of AD-insensitive genes relative to a normalizing
baseline, or from averages of Ca2 + release-stabilizing genes
in non-AD subjects, thereby providing a quantitative index
of deviation that can be used to estimate AD risk or
progression. With clinical experience, estimates based on
this index will be further validated and become increasingly
precise.
In another embodiment, the subject technology relates to
a method for treating AD, early-stage AD, mild cognitive
impairment (MCI), other forms of aging-related cognitive
decline or elevated risk of AD, comprising enhancing activity of one or more Ca2 + release-stabilizing molecules in a
subject diagnosed with one of the above conditions by
injecting the subject in the hippocampus and/or other
affected brain regions with a quantity of inactivated virus
that has been molecularly engineered to overexpress one or
a plurality of genes encoding Ca2 + release-stabilizing molecules, as mentioned above, and assessing the treated subject
over time for improved performance on cognitive/neuropsychological tests. Alternative embodiments of this subject
technology include other delivery methods (eg, non-viralmediated cellular uptake, microinfusions, targeted pharmacological delivery, etc.) of nucleotide sequences that will
increase expression of Ca 2 + -stabilizing molecules in cells in
brain regions affected by AD. Other alternative embodiments include methods that do not rely on gene expression,
but which enhance activity of Ca 2 + release-stabilizing molecules through post-translational modifications, microRNAs or pharmacological targeting of Ca 2 + release-stabilizing molecules or their inhibitors.
Various aspects of the subject technology are described in
further detail in the following subsections:
I. Isolated Nucleic Acid Molecules Encoding Ca 2 + ReleaseStabilizing Molecules
One aspect of the subject technology pertains to isolated
nucleic acid molecules that either themselves are the genetic
targets (e.g., variants of any of the Ca2 + release-stabilizing
molecules disclosed herein) of the subject technology, or
which encode the polypeptide targets of the subject technology, or functional fragments thereof. Another aspect of
the subject technology relates to using the nucleic acid
sequences of Fkbp1a, Fkbp1 b variant_a, Fkbp1 b variant_b,
Junctophilin 3, Junctophilin 4 and Calmodulin 3 to obtain
variant molecules encoding proteins that have similar activity, i.e., calcium release-stabilizing activity for ryanodine
receptors (RyRs), inosital triphosphate receptors (InsP3Rs).
Another aspect of the subject technology pertains to isolated
nucleic acid fragments sufficient for use as hybridization
probes to identifY the nucleic acid molecules encoding the
targets of the subject technology in a sample, as well as
nucleotide fragments for use as PCR primers for the amplification or mutation of the nucleic acid molecules which
encode the targets of the subject technology. As used herein,
the term "nucleic acid molecule" is intended to include DNA
molecules (e.g., eDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA
generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
A nucleic acid molecule of the subject technology, e.g., a
variant ofFKBP1 b, can be isolated using standard molecular
biology techniques and the sequence information provided
herein. Using all or portion of the nucleic acid sequence of
the FKBP gene, e.g., the FKBP1 b as a hybridization probe,

a target gene of the subject technology or a nucleic acid
molecule encoding a polypeptide target of the subject technology can be isolated using standard hybridization and
cloning techniques (e.g., as described in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory,
Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y., 1989).
A nucleic acid of the subject technology can be amplified
using eDNA, mRNA or alternatively, genomic DNA, as a
template and appropriate oligonucleotide primers according
to standard PCR amplification techniques. The nucleic acid
so amplified can be cloned into an appropriate vector and
characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to target nucleotide sequences,
or nucleotide sequences encoding a target of the subject
technology can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In another embodiment, an isolated nucleic acid molecule
of the subject technology comprises a nucleic acid molecule
which is a complement of the nucleotide sequence of a target
of the subject technology or a portion of any of these
nucleotide sequences. A nucleic acid molecule which is
complementary to such a nucleotide sequence is one which
is sufficiently complementary to the nucleotide sequence
such that it can hybridize to the nucleotide sequence, thereby
forming a stable duplex.
The nucleic acid molecule of the subject technology,
moreover, can comprise only a portion of the nucleic acid
sequence of a target nucleic acid of the subject technology,
or a gene encoding a target polypeptide of the subject
technology, for example, a fragment which can be used as a
probe or primer. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7 or 15,
preferably about 20 or 25, more preferably about 50, 75,
100, 125, 150, 175,200, 225,250, 275,300, 325,350, 400
or more consecutive nucleotides of a target nucleic acid, or
a nucleic acid encoding a target polypeptide of the subject
technology.
Probes based on the nucleotide sequence of a target gene
or of a nucleic acid molecule encoding a target polypeptide
of the subject technology can be used to detect transcripts or
genomic sequences corresponding to the target gene( s)
and/or target polypeptide(s) of the subject technology. In
preferred embodiments, the probe comprises a label group
attached thereto, e.g., the label group can be a radioisotope,
a fluorescent compound, an enzyme, or an enzyme co-factor.
Such probes can be used as a part of a diagnostic test kit for
identifying cells or tissue which misexpress (e.g., over- or
under-express) a target polypeptide of the subject technology, or which have greater or fewer copies of a target gene
of the subject technology. For example, a level of a target
polypeptide-encoding nucleic acid in a sample of cells from
a subject may be detected, the amount of mRNA transcript
of a gene encoding a target polypeptide may be determined,
or the presence of mutations or deletions of a target gene of
the subject technology may be assessed.
The subject technology further encompasses nucleic acid
molecules that differ from the nucleic acid sequences of the
gene of the Ca 2 + release-stabilizing molecules of the subject
technology, e.g., FKBP1 b gene, due to degeneracy of the
genetic code and which thus encode the same proteins as
those encoded by the gene of the Ca2 + release-stabilizing
molecules, e.g., FKBP1 b gene.
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It will be appreciated by those skilled in the art that DNA
In addition to naturally-occurring allelic variants of the
sequence polymorphisms can lead to changes in the amino
target gene and gene encoding a target protein of the subject
acid sequences of the proteins encoded by the genes of the
technology sequences that may exist in the population, the
Ca 2 + release-stabilizing molecules of the instant disclosure.
skilled artisan will further appreciate that changes can be
introduced by mutation into the nucleotide sequences of the
Such genetic polymorphism in, for example, the FKBP1 b
target genes or genes encoding the target proteins of the
gene, may exist among individuals within a population due
subject technology, thereby leading to changes in the amino
to natural allelic variation. An allele is one of a group of
genes which occur alternatively at a given genetic locus. In
acid sequence of the encoded proteins, without altering the
addition it will be appreciated that DNA polymorphisms that
functional activity of these proteins. For example, nucleotide
affect RNA expression levels can also exist that may affect 10 substitutions leading to amino acid substitutions at "nonessential" amino acid residues can be made. A "non-essenthe overall expression level of that gene (e.g., by affecting
tial" amino acid residue is a residue that can be altered from
regulation or degradation). As used herein, the phrase
"allelic variant" includes a nucleotide sequence which
the wild-type sequence of a protein without altering the
biological activity, whereas an "essential" amino acid resioccurs at a given locus or to a polypeptide encoded by the
nucleotide sequence. As used herein, the terms "gene" and 15 due is required for biological activity. For example, amino
"recombinant gene" refer to nucleic acid molecules which
acid residues that are conserved among allelic variants or
include an open reading frame encoding a target polypeptide
homologs of a gene (e.g., among homologs of a gene from
of the subject technology.
different species) are predicted to be particularly unamenable to alteration.
Nucleic acid molecules corresponding to natural allelic
variants and homologues of the gene to the Ca 2 + release- 20
Accordingly, another aspect of the subject technology
stabilizing molecules or genes encoding the Ca 2 + releasepertains to nucleic acid molecules encoding a target protein
of the subject technology that contain changes in amino acid
stabilizing molecules can be isolated based on their homology to the gene of the Ca 2 + release-stabilizing molecules
residues that are not essential for activity. Such proteins
using the cDNAs disclosed herein, or a portion thereof, as a
differ in amino acid sequence from the target proteins
hybridization probe according to standard hybridization 25 encoded by the gene of the Ca 2 + release-stabilizing molecules yet retain the same biological activity. In one emboditechniques under stringent hybridization conditions. Nucleic
ment, the protein comprises an amino acid sequence at least
acid molecules corresponding to natural allelic variants and
about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or
homologues of the target genes of the subject technology can
further be isolated by mapping to the same chromosome or
more homologous or identical to a target protein of the
locus as the target genes or genes encoding the target 30 subject technology.
An isolated nucleic acid molecule encoding a protein
proteins of the subject technology.
homologous to a target protein of the subject technology can
In another embodiment, an isolated nucleic acid molecule
of the subject technology is at least 15, 20, 25, 30, 50, 100,
be created by introducing one or more nucleotide substitu150,200,250,300,350,400,450,500,550,600,650,700,
tions, additions or deletions into the nucleotide sequence of
750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 35 the gene encoding the target protein, such that one or more
amino acid substitutions, additions or deletions are intro1500, 1600, 1700, 1800, 1900, 2000 or more nucleotides in
duced into the encoded protein. Mutations can be introduced
length and hybridizes under stringent conditions to a nucleic
into the gene of the Ca 2 + release-stabilizing molecules, e.g.,
acid molecule corresponding to a nucleotide sequence of a
FKBP1 b gene, of the subject technology by standard techtarget gene or gene encoding a target protein of the subject
technology. As used herein, the term "hybridizes under 40 niques, such as site-directed mutagenesis and PCR -mediated
stringent conditions" is intended to describe conditions for
mutagenesis. Preferably, conservative amino acid substituhybridization and washing under which nucleotide
tions are made at one or more predicted non-essential amino
acid residues. A "conservative amino acid substitution" is
sequences at least 60% sequence identity (over their entire
one in which the amino acid residue is replaced with an
lengths) to each other typically remain hybridized to each
other. Generally, percent homology or identity is based on 45 amino acid residue having a similar side chain. Families of
two polynucleotide strands that are comparable in length the
amino acid residues having similar side chains have been
percent value reflects homology throughout the length of the
defined in the art. These families include amino acids with
two strands. Preferably, the conditions are such that
basic side chains (e.g., lysine, arginine, histidine), acidic
side chains (e.g., aspartic acid, glutamic acid), uncharged
sequences at least about 70%, more preferably at least about
80%, even more preferably at least about 85% or 90% 50 polar side chains (e.g., glycine, asparagine, glutamine, serhomologous to each other (over their entire lengths or
ine, threonine, tyrosine, cysteine), nonpolar side chains (e.g.,
throughout their lengths) typically remain hybridized to each
alanine, valine, leucine, isoleucine, proline, phenylalanine,
other. Such stringent conditions are known to those skilled
methionine, tryptophan), beta-branched side chains (e.g.,
threonine, valine, isoleucine) and aromatic side chains (e.g.,
in the art and can be found in Current Protocols in Molecular
Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A 55 tyrosine, phenylalanine, tryptophan, histidine). Alternapreferred, non-limiting example of stringent hybridization
tively, mutations can be introduced randomly along all or
part of a coding sequence of a gene of the subject technolconditions are hybridization in 6x sodium chloride/sodium
ogy, such as by saturation mutagenesis, and the resultant
citrate (SSC) at about 45° C., followed by one or more
washes in 0.2xSSC, 0.1% SDS at 50° C., preferably at 55°
mutants can be screened for biological activity to identifY
C., more preferably at 60° C., and even more preferably at 60 mutants that retain activity. Following mutagenesis, the
65° C. Preferably, an isolated nucleic acid molecule of the
encoded protein can be expressed recombinantly and the
subject technology that hybridizes under stringent condiactivity of the protein can be determined.
tions to the sequence of the gene of the Ca2 + releaseIn yet another embodiment, the nucleic acid molecules of
stabilizing molecules, e.g., FKBP1b gene. As used herein, a
the present subject technology can be modified at the base
"naturally-occurring" nucleic acid molecule includes an 65 moiety, sugar moiety or phosphate backbone to improve,
RNA or DNA molecule having a nucleotide sequence that
e.g., the stability, hybridization, or solubility of the moloccurs in nature (e.g. encodes a natural protein).
ecule. For example, the deoxyribose phosphate backbone of
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the nucleic acid molecules can be modified to generate
peptide nucleic acids (see Hyrup B. eta!. (1996) Bioorganic
& Medicinal Chemistry 4 (1): 5-23). As used herein, the
terms "peptide nucleic acids" or "PNAs" refer to nucleic
acid mimics, e.g., DNA mimics, in which the deoxyribose
phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The
neutral backbone of PNAs has been shown to allow for
specific hybridization to DNA and RNA under conditions of
low ionic strength. The synthesis of PNA oligomers can be
performed using standard solid phase peptide synthesis
protocols as described in Hyrup B. et a!. (1996) supra;
Perry-O'Keefe et a!. Proc. Nat!. Acad. Sci. 93: 14670-675.
In other embodiments, the oligonucleotide may include
other appended groups such as peptides (e.g., for targeting
host cell receptors in vivo), or agents facilitating transport
across the cell membrane (see, e.g., Letsinger eta!. (1989)
Proc. Nat!. Acad. Sci. USA 86:6553-6556; Lemaitre et a!.
(1987) Proc. Nat!. Acad. Sci. USA 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see,
e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered
cleavage agents (See, e.g., Krol eta!. (1988) Bio-Techniques
6:958-976) or intercalating agents. (See, eg., Zon (1988)
Pharm. Res. 5:539-549). To this end, the oligonucleotide
may be conjugated to another molecule, (e.g., a peptide,
hybridization triggered cross-linking agent, transport agent,
or hybridization-triggered cleavage agent). Finally, the oligonucleotide may be detectably labeled, either such that the
label is detected by the addition of another reagent (e.g. a
substrate for an enzymatic label), or is detectable immediately upon hybridization of the nucleotide (e.g., a radioactive label or a fluorescent label (e.g., a molecular beacon, as
described in U.S. Pat. No. 5,876,930.
II. Isolated Proteins and Antibodies
One aspect of the subject technology pertains to isolated
target proteins i.e., the Ca 2 + release-stabilizing molecules,
e.g., Fkbp1a, Fkbp1 b variant_a, Fkbp1 b variant_b, Junctophilin 3, Junctophilin 4 and Calmodulin 3, and biologically
or functionally active portions thereof suitable for use as
therapeutic molecules for stabilizing calcium release from
ryanodine receptors (RyRs), inosital triphosphate receptors
(InsP3Rs). Alternatively, the isolated target proteins i.e., the
Ca 2 + release-stabilizing molecules, e.g., Fkbp1a, Fkbp1 b
variant_a, Fkbp1 b variant_b, Junctophilin 3, Junctophilin 4
and Calmodulin 3, and biologically or functionally active
portions thereof suitable for use are used as immunogens to
raise anti-target protein antibodies. In one embodiment,
native target proteins can be isolated from cells or tissue
sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, target proteins are produced by recombinant DNA
techniques. Alternative to recombinant expression, a target
protein or polypeptide can be synthesized chemically using
standard peptide synthesis techniques.
An "isolated" or "purified" protein or biologically active
portion thereof is substantially free of cellular material or
other contaminating proteins from the cell or tissue source
from which the target protein is derived, or substantially free
from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of target protein in
which the protein is separated from cellular components of
the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free
of cellular material" includes preparations of target protein
having less than about 30% (by dry weight) of non-target

protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-target
protein, still more preferably less than about 10% of nontarget protein, and most preferably less than about 5%
non-target protein. When the target protein or biologically
active portion thereof is recombinantly produced, it is also
preferably substantially free of culture medium, i.e., culture
medium represents less than about 20%, more preferably
less than about 10%, and most preferably less than about 5%
of the volume of the protein preparation.
The language "substantially free of chemical precursors
or other chemicals" includes preparations of target protein in
which the protein is separated from chemical precursors or
other chemicals which are involved in the synthesis of the
protein. In one embodiment, the language "substantially free
of chemical precursors or other chemicals" includes preparations of protein having less than about 30% (by dry
weight) of chemical precursors or non-protein chemicals,
more preferably less than about 20% chemical precursors or
non-protein chemicals, still more preferably less than about
10% chemical precursors or non-protein chemicals, and
most preferably less than about 5% chemical precursors or
non-protein chemicals.
As used herein, a "biologically active portion" or "functiona! fragment" (as used interchangeably) of a target protein includes a fragment of a target protein comprising
amino acid sequences sufficiently homologous to or derived
from the amino acid sequence of the target protein, which
include fewer amino acids than the full length target proteins, and exhibit at least one activity of a target protein, i.e.,
Ca 2 + release-stabilizing activity on RyRs or InsP3Rs. Typically, biologically active portions comprise a domain or
motif with at least one activity of the target protein. A
biologically active portion of a target protein can be a
polypeptide which is, for example, 10, 25, 50, 100, 200 or
more amino acids in length. Biologically active portions of
a target protein can be used as targets for developing agents
which modulate a target protein-mediated activity.
In a preferred embodiment, target protein is encoded by
the gene of the Ca 2 + release-stabilizing molecules. In other
embodiments, the target protein is substantially homologous
to a target protein encoded by the genes of the Ca 2 +
release-stabilizing molecules, e.g., FKBP1 b gene, and
retains the functional activity of the target protein, yet differs
in amino acid sequence due to natural allelic variation or
mutagenesis, as described in detail in subsection I above.
Accordingly, in another embodiment, the target protein is a
protein which comprises an amino acid sequence with at
least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98% or more sequence identity to the amino acid sequence
encoded by the genes of the Ca2 + release-stabilizing molecules, e.g., FKBP1b gene.
To determine the percent identity of two amino acid
sequences or of two nucleic acid sequences, the sequences
are aligned for optimal comparison purposes (e.g., gaps can
be introduced in one or both of a first and a second amino
acid or nucleic acid sequence for optimal aligument and
non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a
reference sequence aligned for comparison purposes is at
least 30%, preferably at least 40%, more preferably at least
50%, even more preferably at least 60%, and even more
preferably at least 70%, 80%, or 90% of the length of the
reference sequence. The amino acid residues or nucleotides
at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first
sequence is occupied by the same amino acid residue or
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nucleotide as the corresponding pos1t!on in the second
sequence, then the molecules are identical at that position (as
used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent
identity between the two sequences is a function of the
number of identical positions shared by the sequences,
taking into account the number of gaps, and the length of
each gap, which need to be introduced for optimal alignment
of the two sequences.
The comparison of sequences and determination of percent identity between two sequences can be accomplished
using a mathematical algorithm. In a preferred embodiment,
the percent identity between two amino acid sequences is
determined using the Needleman and Wunsch (J. Mat. Bioi.
(48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package,
using either a Blossom 62 matrix or a PAM250 matrix, and
a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight
of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment,
the percent identity between two nucleotide sequences is
determined using the GAP program in the GCG software
package, using a NWSgapdna.CMP matrix and a gap weight
of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5,
or 6. In another embodiment, the percent identity between
two amino acid or nucleotide sequences is determined using
the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17
(1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a
gap length penalty of 12 and a gap penalty of 4.
The nucleic acid and protein sequences of the present
subject technology can further be used as a "query
sequence" to perform a search against public databases to,
for example, identifY other family members or related
sequences. Such searches can be performed using the
NBLAST and XBLAST programs (version 2.0) of Altschul,
eta!. (1990) J. Mol. Bioi. 215:403-10. BLAST nucleotide
searches can be performed with the NBLAST program,
score= 100, wordlength= 12 to obtain nucleotide sequences
homologous to nucleic acid molecules of the subject technology. BLAST protein searches can be performed with the
XBLAST program, score=50, wordlength=3 to obtain
amino acid sequences homologous to target protein molecules of the subject technology. To obtain gapped alignments for comparison purposes, Gapped BLAST can be
utilized as described in Altschul eta!., (1997) Nucleic Acids
Res. 25(17):3389-3402. When utilizing BLAST and Gapped
BLAST programs, the default parameters of the respective
programs (e.g., XBLAST and NBLAST) can be used.
The subject technology also provides chimeric or fusion
target proteins. As used herein, a target "chimeric protein" or
"fusion protein" comprises a target polypeptide operatively
linked to a non-target polypeptide. A "target polypeptide"
includes a polypeptide having an amino acid sequence
encoded by the genes of the Ca 2 + release-stabilizing molecules, e.g., FKBP1b gene, whereas a "non-target polypeptide" includes a polypeptide having an amino acid sequence
corresponding to a protein which is not substantially
homologous to the target protein, e.g., a protein which is
different from target protein and which is derived from the
same or a different organism. Within a target fusion protein
the polypeptide can correspond to all or a portion of a target
protein. In a preferred embodiment, a target fusion protein
comprises at least one biologically active portion of a target
protein. Within the fusion protein, the term "operatively
linked" is intended to indicate that the target polypeptide and
the non-target polypeptide are fused in-frame to each other.

The non-target polypeptide can be fused to theN-terminus
or C-terminus of the target polypeptide.
For example, in one embodiment, the fusion protein is a
GST-target fusion protein in which the target sequences are
fused to the C-terminus of the GST sequences. Such fusion
proteins can facilitate the purification of recombinant target
proteins.
In another embodiment, the fusion protein is a target
protein containing a heterologous signal sequence at its
N-terminus. In certain host cells (e.g., mammalian host
cells), expression and/or secretion of target proteins can be
increased through use of a heterologous signal sequence.
Such signal sequences are well known in the art.
The target fusion proteins of the subject technology can be
incorporated into pharmaceutical compositions and administered to a subject in vivo, as described herein. The target
fusion proteins can be used to affect the bioavailability of a
target protein substrate. Use of target fusion proteins may be
useful therapeutically for the treatment of disorders (e.g.,
AD, MCI or other cognitive impairments) caused by, for
example, (i) aberrant modification or mutation of a gene
encoding a target protein; (ii) mis-regulation of the target
protein-encoding gene; and (iii) aberrant post-translational
modification of a target protein.
Moreover, the target-fusion proteins of the subject technology can be used as immunogens to produce anti-target
protein antibodies in a subject, to purifY target protein
ligands and in screening assays to identifY molecules which
inhibit the interaction of a target protein with a target protein
substrate.
Preferably, a target chimeric or fusion protein of the
subject technology is produced by standard recombinant
DNA techniques. For example, DNA fragments coding for
the different polypeptide sequences are ligated together
in-frame in accordance with conventional techniques, for
example by employing blunt-ended or stagger-ended termini
for ligation, restriction enzyme digestion to provide for
appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable
joining, and enzymatic ligation. In another embodiment, the
fusion gene can be synthesized by conventional techniques
including automated DNA synthesizers. Alternatively, PCR
amplification of gene fragments can be carried out using
anchor primers which give rise to complementary overhangs
between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric
gene sequence (see, for example, Current Protocols in
Molecular Biology, eds. Ausubel et a!. John Wiley & Sons:
1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a
GST polypeptide). A target protein-encoding nucleic acid
can be cloned into such an expression vector such that the
fusion moiety is linked in-frame to the target protein.
A signal sequence can be used to facilitate secretion and
isolation of the secreted protein or other proteins of interest.
Signal sequences are typically characterized by a core of
hydrophobic amino acids which are generally cleaved from
the mature protein during secretion in one or more cleavage
events. Such signal peptides contain processing sites that
allow cleavage of the signal sequence from the mature
proteins as they pass through the secretory pathway. Thus,
the subject technology pertains to the described polypeptides
having a signal sequence, as well as to polypeptides from
which the signal sequence has been proteolytically cleaved
(i.e., the cleavage products). In one embodiment, a nucleic
acid sequence encoding a signal sequence can be operably
linked in an expression vector to a protein of interest, such
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as a protein which is ordinarily not secreted or is otherwise
difficult to isolate. The signal sequence directs secretion of
the protein, such as from a eukaryotic host into which the
expression vector is transformed, and the signal sequence is
subsequently or concurrently cleaved. The protein can then
be readily purified from the extracellular medium by art
recognized methods. Alternatively, the signal sequence can
be linked to the protein of interest using a sequence which
facilitates purification, such as with a GST domain.
The present subject technology also pertains to variants of
the target proteins of the subject technology which function
as either agonists (mimetics) or as antagonists to the target
proteins. Variants of the target proteins can be generated by
mutagenesis, e.g., discrete point mutation or truncation of a
target protein. An agonist of the target proteins can retain
substantially the same, or a subset, of the biological activities of the naturally occurring form of a target protein. An
antagonist of a target protein can inhibit one or more of the
activities of the naturally occurring form of the target protein
by, for example, competitively modulating an activity of a
target protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one
embodiment, treatment of a subject with a variant having a
subset of the biological activities of the naturally occurring
form of the protein has fewer side effects in a subject relative
to treatment with the naturally occurring form of the target
protein.
Variants of a target protein which function as either target
protein agonists (mimetics) or as target protein antagonists
can be identified by screening combinatorial libraries of
mutants, e.g., truncation mutants, of a target protein for
target protein agonist or antagonist activity. In one embodiment, a variegated library of target protein variants is
generated by combinatorial mutagenesis at the nucleic acid
level and is encoded by a variegated gene library. A variegated library of target protein variants can be produced by,
for example, enzymatically ligating a mixture of synthetic
oligonucleotides into gene sequences such that a degenerate
set of potential target protein sequences is expressible as
individual polypeptides, or alternatively, as a set of larger
fusion proteins (e.g., for phage display) containing the set of
target protein sequences therein. There are a variety of
methods which can be used to produce libraries of potential
target protein variants from a degenerate oligonucleotide
sequence. Chemical synthesis of a degenerate gene sequence
can be performed in an automatic DNA synthesizer, and the
synthetic gene then ligated into an appropriate expression
vector. Use of a degenerate set of genes allows for the
provision, in one mixture, of all of the sequences encoding
the desired set of potential target protein sequences. Methods for synthesizing degenerate oligonucleotides are known
in the art (see, e.g., Narang, S. A. (1983) Tetrahedron 39:3;
Itakura eta!. (1984) Annu. Rev. Biochem. 53:323; Itakura et
a!. (1984) Science 198:1056; Ike eta!. (1983) Nucleic Acid
Res. 11:477).
In addition, libraries of fragments of a protein coding
sequence corresponding to a target protein of the subject
technology can be used to generate a variegated population
of target protein fragments for screening and subsequent
selection of variants of a target protein. In one embodiment,
a library of coding sequence fragments can be generated by
treating a double stranded PCR fragment of a target protein
coding sequence with a nuclease under conditions wherein
nicking occurs only about once per molecule, denaturing the
double stranded DNA, renaturing the DNA to form double
stranded DNA which can include sense/antisense pairs from
different nicked products, removing single stranded portions

from reformed duplexes by treatment with S1 nuclease, and
ligating the resulting fragment library into an expression
vector. By this method, an expression library can be derived
which encodes N-terminal, C-terminal and internal fragments of various sizes of the target protein.
Several techniques are known in the art for screening gene
products of combinatorial libraries made by point mutations
or truncation, and for screening eDNA libraries for gene
products having a selected property. The most widely used
techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include
cloning the gene library into replicable expression vectors,
transforming appropriate cells with the resulting library of
vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates
isolation of the vector encoding the gene whose product was
detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in
the libraries, can be used in combination with the screening
assays to identifY target variants (Arkin and Yourvan (1992)
Proc. Nat!. Acad. Sci. USA 89:7811-7815; Delgrave eta!.
(1993) Protein Engineering 6(3):327-331).
An isolated target protein, or a portion or fragment
thereof, can be used as an immunogen to generate antibodies
that bind target proteins using standard techniques for polyclonal and monoclonal antibody preparation. A full-length
target protein can be used or, alternatively, the subject
technology provides antigenic peptide fragments of these
proteins for use as immunogens. The antigenic peptide of a
target protein comprises at least 8 amino acid residues of an
amino acid sequence encoded by the FKBP1b gene, and
encompasses an epitope of a target protein such that an
antibody raised against the peptide forms a specific immune
complex with the target protein. Preferably, the antigenic
peptide comprises at least 10 amino acid residues, more
preferably at least 15 amino acid residues, even more
preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.
III. Recombinant Expression Vectors and Host Cells
Another aspect of the subject technology pertains to
vectors, preferably expression vectors, containing a nucleic
acid encoding a target protein, i.e., a Ca2 + release-stabilizing
molecule, e.g., Fkbp1a, Fkbp1b variant_a, Fkbp1b variant_b, Junctophilin 3, Junctophilin 4 and Calmodulin 3 and
biologically or functionally active portions thereof, of the
subject technology. As used herein, the term "vector"
includes a nucleic acid molecule capable of transporting
another nucleic acid to which it has been linked. One type
of vector is a "plasmid", which includes a circular double
stranded DNA loop into which additional DNA segments
can be ligated. Another type of vector is a viral vector,
wherein additional DNA segments can be ligated into the
viral genome. Certain vectors are capable of autonomous
replication in a host cell into which they are introduced (e.g.,
bacterial vectors having a bacterial origin of replication and
episomal mammalian vectors). Other vectors (e.g., nonepisomal mammalian vectors) are integrated into the
genome of a host cell upon introduction into the host cell,
and thereby are replicated along with the host genome.
Moreover, certain vectors are capable of directing the
expression of genes to which they are operatively linked.
Such vectors are referred to herein as "expression vectors".
In general, expression vectors of utility in recombinant DNA
techniques are often in the form of plasmids. In the present
specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form
of vector. However, the subject technology is intended to
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include such other forms of expression vectors, such as viral
vectors (e.g. replication defective retroviruses, adenoviruses
and adena-associated viruses), which serve equivalent functions.
The recombinant expression vectors of the subject technology comprise a nucleic acid of the subject technology in
a form suitable for expression of the nucleic acid in a host
cell, which means that the recombinant expression vectors
include one or more regulatory sequences, selected on the
basis of the host cells to be used for expression, which is
operatively linked to the nucleic acid sequence to be
expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide
sequence of interest is linked to the regulatory sequence(s)
in a manner which allows for expression of the nucleotide
sequence (e.g., in an in vitro transcription/translation system
or in a host cell when the vector is introduced into the host
cell). The term "regulatory sequence" is intended to include
promoters, enhancers and other expression control elements
(e.g., polyadenylation signals). Such regulatory sequences
are described, for example, in Goedde!; Gene Expression
Technology: Methods in Enzymology 185, Academic Press,
San Diego, Calif. (1990). Regulatory sequences include
those which direct constitutive expression of a nucleotide
sequence in many types of host cells and those which direct
expression of the nucleotide sequence only in certain host
cells (e.g., tissue-specific regulatory sequences). It will be
appreciated by those skilled in the art that the design of the
expression vector can depend on such factors as the choice
of the host cell to be transformed, the level of expression of
protein desired, and the like. The expression vectors of the
subject technology can be introduced into host cells to
thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described
herein (e.g., target proteins, mutant forms of target proteins,
fusion proteins, and the like).
The recombinant expression vectors of the subject technology can be designed for expression of target proteins in
prokaryotic or eukaryotic cells. For example, target proteins
can be expressed in bacterial cells such as E. coli, insect cells
(using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in
Goedde!, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).
Alternatively, the recombinant expression vector can be
transcribed and translated in vitro, for example using T7
promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or
inducible promoters directing the expression of either fusion
or non-fusion proteins. Fusion vectors add a number of
amino acids to a protein encoded therein, usually to the
amino terminus of the recombinant protein. Such fusion
vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of
the recombinant protein; and 3) to aid in the purification of
the recombinant protein by acting as a ligand in affinity
purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the
fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety
subsequent to purification of the fusion protein. Such
enzymes, and their cognate recognition sequences, include
Factor Xa, thrombin and enterokinase. Typical fusion
expression vectors include pGEX (Pharmacia Biotech Inc;
Smith, D. B. and Johnson, K. S. (1988) Gene 67:31-40),
pMAL (New England Biolabs, Beverly, Mass.) and pRITS

(Pharmacia, Piscataway, N.J.) which fuse glutathione
S-transferase (GST), maltose E binding protein, or protein
A, respectively, to the target recombinant protein.
Purified fusion proteins can be utilized in target activity
assays, (e.g., direct assays or competitive assays described in
detail below), or to generate antibodies specific for target
proteins, for example.
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et a!., (1988) Gene
69:301-315) and pET 11d (Studier eta!., Gene Expression
Technology: Methods in Enzymology 185, Academic Press,
San Diego, Calif. (1990) 60-89). Target gene expression
from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene
expression from the pET 11d vector relies on transcription
from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174
(DE3) from a resident prophage harboring a T7 gn1 gene
under the transcriptional control of the lacUV 5 promoter.
One strategy to maximize recombinant protein expression
in E. coli is to express the protein in a host bacteria with an
impaired capacity to proteolytically cleave the recombinant
protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif.
(1990) 119-128). Another strategy is to alter the nucleic acid
sequence of the nucleic acid to be inserted into an expression
vector so that the individual codons for each amino acid are
those preferentially utilized in E. coli (Wada eta!., (1992)
Nucleic Acids Res. 20:2111-2118). Such alteration of
nucleic acid sequences of the subject technology can be
carried out by standard DNA synthesis techniques.
In another embodiment, the target protein expression
vector is a yeast expression vector. Examples of vectors for
expression in yeastS. cerevisiae include p Yep Sec 1 (Baldari,
et a!., (1987) Embo J. 6:229-234), pMFa (Kmjan and
Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et
a!., (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San
Diego, Calif.).
Alternatively, target proteins of the subject technology
can be expressed in insect cells using baculovirus expression
vectors. Baculovirus vectors available for expression of
proteins in cultured insect cells (e.g., Sf 9 cells) include the
pAc series (Smith et a!. (1983) Mol. Cell. Bioi. 3:21562165) and the pVL series (Lucklow and Summers (1989)
Virology 170:31-39).
In yet another embodiment, a nucleic acid of the subject
technology is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:
840) and pMT2PC (Kaufman eta!. (1987) EMBO J. 6:187195). When used in mammalian cells, the expression
vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are
derived from polyoma, Adenovirus 2, cytomegalovirus and
Simian Virus 40. For other suitable expression systems for
both prokaryotic and eukaryotic cells see chapters 16 and 17
of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular
Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y., 1989.
In another embodiment, the recombinant mmalian
expression vector is capable of directing expression of the
nucleic acid preferentially in a particular cell type (e.g.,
tissue-specific regulatory elements are used to express the
nucleic acid). Tissue-specific regulatory elements are known
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in the art. Non-limiting examples of suitable tissue-specific
promoters include the albumin promoter (liver-specific;
Pinkert et a!. (1987) Genes Dev. 1:268-277), lymphoidspecific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters ofT cell receptors
(Winoto and Baltimore (1989) EMBO J. 8:729-733) and
immunoglobulins (Banerji et a!. (1983) Cell 33:729-740;
Queen and Baltimore (1983) Cell 33:741-748), neuronspecific promoters (e.g., the neurofilament promoter; Byrne
and Ruddle (1989) Proc. Nat!. Acad. Sci. USA 86:54735477), pancreas-specific promoters (Edlund et a!. (1985)
Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316
and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for
example the murine hox promoters (Kessel and Gruss
(1990) Science 249:374-379) and the fetoprotein promoter
(Campes and Tilghman (1989) Genes Dev. 3:537-546).
Another aspect of the subject technology pertains to host
cells into which a nucleic acid molecule of the subject
technology is introduced, e.g., genes of the Ca 2 + releasestabilizing molecules, e.g., FKBP1 b gene within a recombinant expression vector or a nucleic acid molecule of the
subject technology containing sequences which allow it to
homologously recombine into a specific site of the host
cell's genome. The terms "host cell" and "recombinant host
cell" are used interchangeably herein. It is understood that
such terms refer not only to the particular subject cell but to
the progeny or potential progeny of such a cell. Because
certain modifications may occur in succeeding generations
due to either mutation or environmental influences, such
progeny may not, in fact, be identical to the parent cell, but
are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For
example, a target protein of the subject technology can be
expressed in bacterial cells such as E. coli, insect cells, yeast
or mammalian cells (such as Chinese hamster ovary cells
(CHO) or COS cells). Other suitable host cells are known to
those skilled in the art.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection
techniques. As used herein, the terms "transformation" and
"transfection" are intended to refer to a variety of artrecognized techniques for introducing foreign nucleic acid
(e.g., DNA) into a host cell, including calcium phosphate or
calcium chloride co-precipitation, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found
in Sambrook, et a!. (Molecular Cloning: A Laboratory
Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.,
1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known
that, depending upon the expression vector and transfection
technique used, only a small fraction of cells may integrate
the foreign DNA into their genome. In order to identifY and
select these integrants, a gene that encodes a selectable
target (e.g., resistance to antibiotics) is generally introduced
into the host cells along with the gene of interest. Preferred
selectable targets include those which confer resistance to
drugs, such as G418, hygromycin and methotrexate. Nucleic
acid encoding a selectable target can be introduced into a
host cell on the same vector as that encoding a target protein
or can be introduced on a separate vector. Cells stably
transfected with the introduced nucleic acid can be identified
by drug selection (e.g., cells that have incorporated the
selectable target gene will survive, while the other cells die).

A host cell of the subject technology, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce
(i.e., express) a target protein. Accordingly, the subject
technology further provides methods for producing a target
protein using the host cells of the subject technology. In one
embodiment, the method comprises culturing the host cell of
subject technology (into which a recombinant expression
vector encoding a target protein has been introduced) in a
suitable medium such that a target protein of the subject
technology is produced. In another embodiment, the method
further comprises isolating a target protein from the medium
or the host cell. The host cells of the subject technology can
also be used to produce non-human transgenic animals. For
example, in one embodiment, a host cell of the subject
technology is a fertilized oocyte or an embryonic stem cell
into which target-protein-coding sequences have been introduced. Such host cells can then be used to create non-human
transgenic animals in which exogenous sequences encoding
a target protein of the subject technology have been introduced into their genome or homologous recombinant animals in which endogenous sequences encoding the target
proteins of the subject technology have been altered. Such
animals are useful for studying the function and/or activity
of a target protein and for identifying and/or evaluating
modulators of target protein activity. As used herein, a
"transgenic animal" is a non-human animal, preferably a
mammal, more preferably a rodent such as a rat or mouse,
in which one or more of the cells of the animal includes a
transgene. Other examples of transgenic animals include
non-human primates, sheep, dogs, cows, goats, chickens,
amphibians, and the like. A transgene is exogenous DNA
which is integrated into the genome of a cell from which a
transgenic animal develops and which remains in the
genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types
or tissues of the transgenic animal. As used herein, a
"homologous recombinant animal" is a non-human animal,
preferably a mmal, more preferably a mouse, in which an
endogenous FKBP1b gene has been altered by homologous
recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal,
e.g., an embryonic cell of the animal, prior to development
of the animal.
A transgenic animal of the subject technology can be
created by introducing a target-encoding nucleic acid into
the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to
develop in a pseudopregnant female foster animal. Intronic
sequences and polyadenylation signals can also be included
in the transgene to increase the efficiency of expression of
the transgene. A tissue-specific regulatory sequence(s) can
be operably linked to a transgene to direct expression of a
target protein to particular cells. Methods for generating
transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become
conventional in the art and are described, for example, in
U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Lederet a!.,
U.S. Pat. No. 4,873,191 by Wagner eta!. and in Hogan, B.,
Manipulating the Mouse Embryo, (Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar
methods are used for production of other transgenic animals.
A transgenic founder animal can be identified based upon
the presence of a trans gene of the subject technology in its
genome and/or expression of mRNA corresponding to a
gene of the subject technology in tissues or cells of the
animals. A transgenic founder animal can then be used to
breed additional animals carrying the transgene. Moreover,
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transgenic animals carrying a transgene encoding a target
protein can further be bred to other transgenic animals
carrying other transgenes.
IV. Pharmaceutical Compositions
The molecules of the subject technology i.e. the Ca 2 +
release-stabilizing molecules (including polypeptides, polynucleotides, small molecules or large molecules that can
bind to and enhance the activity or stability of the proteins
of the subject technology (including Fkbp1a, Fkbp1b variant_a, Fkbp1b variant_b, Junctophilin 3, Junctophilin 4 and
Calmodulin 3, ryanodine receptors (RyRs), inosital triphosphate receptors (InsP3Rs)) can be incorporated into pharmaceutical compositions suitable for administration. Such
compositions typically comprise the nucleic acid molecule,
protein, or small molecules and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically
acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the
like, compatible with pharmaceutical administration. The
use of such media and agents for pharmaceutically active
substances is well known in the art. Except insofar as any
conventional media or agent is incompatible with the active
compound, use thereof in the compositions is contemplated.
Supplementary active compounds can also be incorporated
into the compositions.
The subject technology includes methods for preparing
pharmaceutical compositions for modulating the expression
or activity of a ryanodine receptor (RyR), inosital triphosphate receptor (InsP3R) or a polypeptide or nucleic acid
corresponding to a Ca 2 + release-stabilizing molecule of the
subject technology. Such methods comprise formulating a
pharmaceutically acceptable carrier with an agent which
modulates expression or activity of a polypeptide or nucleic
acid corresponding to a target of the subject technology.
Such compositions can further include additional active
agents. Thus, the subject technology further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent
which modulates expression or activity of a polypeptide or
nucleic acid corresponding to a target of the subject technology and one or more additional active compounds.
V. Drug Screening Assays
The subject technology also provides methods (also
referred to herein as "screening assays") for identifying
modulators, i.e., candidate or test compounds or agents (e.g.
peptides, peptidomimetics, peptoids, small molecules or
large molecules or other drugs) which (a) bind to the target
(i.e., FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4,
calmodulin 3, RyRs, InsP3Rs, a variant thereof or a functiona! fragment thereof), or (b) have a modulatory (e.g.,
stimulatory or inhibitory) effect on the activity of the target
or, more specifically, (c) have a modulatory effect on the

interactions of the target with one or more of its natural
substrates (e.g., peptide, protein, hormone, co-factor, or
nucleic acid), or (d) have a modulatory effect on the expression of the target. Such assays typically comprise a reaction
between the target and one or more assay components. The
other components may be either the test compound itself, or
a combination of test compound and a natural binding
partner of the target.
The test compounds of the present subject technology
may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test
compounds may also be obtained by any of the numerous
approaches in combinatorial library methods known in the
art, including: biological libraries; peptoid libraries (libraries
of molecules having the functionalities of peptides, but with
a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive;
see, e.g., Zuckermarm eta!., 1994, J. Med. Chern. 37:267885); spatially addressable parallel solid phase or solution
phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and
synthetic library methods using affinity chromatography
selection. The biological library and peptoid library
approaches are limited to peptide libraries, while the other
four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam,
1997, Anticancer Drug Des. 12:145).
In one exemplary assay format, the ability of a molecule
to modulate the expression and/or the function of a gene or
protein of the subject technology is assayed by monitoring
the expression and/or function of said gene or protein in cell
lines which were exposed to the molecule and comparing
said expression to that in cell lines which were not exposed
to the molecule. Such monitoring can be done using standard
procedures such those disclosed in Sambrook eta!., (1989)
Molecular Cloning-A Laboratory Manual, Cold Spring
Harbor Laboratory Press).
Molecules that are assayed in the above methods can be
randomly selected or rationally selected or designed. As
used herein, a molecule is said to be randomly selected when
the molecule is chosen randomly without considering the
specific sequences involved in the association of the a
protein of the subject technology alone or with its associated
substrates, binding partners, etc. An example of randomly
selected molecules is the use a chemical library or a peptide
combinatorial library, or a growth broth of an organism.
VI. Routes of Administration
A pharmaceutical composition or polypeptide, polynucleotide, small molecule or large molecule of the subject
technology is formulated to be compatible with its intended
route of administration. Examples of routes of administration and dosage forms of such formulations are shown in the
Table below.
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Routes of administration/Dosage forms

Oral

Digestive tract
(enteral)

Solids
Liquids

Buccal/
Sub labial/
Sublingual
Respiratory
tract

Solids
Liquids
Solids
Liquids

Pill, Tablet, Capsule, Time release technology,
Osmotic controlled release capsule (OROS)
Solution, Softgel, Suspension, Emulsion,
Syrup, Elixir, Tincture, Hydrogel
Orally Disintegrating Tablet (ODT), Film,
Lollipop, Lozenges, Chewing gum
Mouthwash, Toothpaste, Ointment, Oral spray
Smoking device Dry Powder Inhaler (DPI)
pressurized Metered Dose Inhaler (pMDI),
Nebulizer, Vaporizer
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-continued

Routes of administration/Dosage forms

Gas

Ophthalmic/
Otologic/
Nasal
Urogenital

Oxygen mask, Oxygen concentrator,
Anaesthetic machine, Relative analgesia
machine
Nasal spray, Ear drops, Eye drops, Ointment, Hydrogel, Nanosphere
suspension, Mucoadhesive microdisc (microsphere tablet)

Ointment, Pessary (vaginal suppository), Vaginal ring, Vaginal douche,
Intrauterine device (IUD), Extra-anmiotic infusion, Intravesical infusion
Rectal
Ointment, Suppository, Enema (Solution, Hydrogel), Murphy drip, Nutrient
enema
(enteral)
Ointment, Liniment, Paste, Film, Hydrogel, Liposomes, Transfersome
Dermal
vesicles, Cream, Lotion, Lip balm, Medicated shampoo, Dermal patch,
Transdermal patch, Transdermal spray, Jet injector
Injection/
Skin
Intradermal, Subcutaneous, Transdermal implant
Infusion
Organs
Intracavernous, Intravitreal, Intra-articular, or
intrasynovial injection, Transscleral
(into
tissue/blood) Central nervous
Intracerebral, Intrathecal, Epidural
system
Circulatory/
Intravenous, Intracardiac, Intramuscular, Intraosseous,
Musculoskeletal
Intraperitoneal, Nanocell injection

Alternative or additional examples of routes of administration include parenteral, e,g,, intravenous, intradermal,
subcutaneous, oral (e,g,, inhalation), transdermal (topical),
transmucosal, and rectal administration, Solutions or suspensions used for parenteral, intradermal, or subcutaneous
application can include the following components: a sterile
diluent such as water for injection, saline solution, fixed oils,
polyethylene glycols, glycerine, propylene glycol or other
synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or
sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or
phosphates and agents for the adjustment of tonicity such as
sodium chloride or dextrose, pH can be adjusted with acids
or bases, such as hydrochloric acid or sodium hydroxide,
The parenteral preparation can be enclosed in ampoules,
disposable syringes or multiple dose vials made of glass or
plastic,
Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or dispersion, For
intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™
(BASF, Parsippany, N,J,) or phosphate buffered saline
(PBS), In all cases, the composition must be sterile and
should be fluid to the extent that easy syringability exists, It
must be stable under the conditions of manufacture and
storage and must be preserved against the contaminating
action of microorganisms such as bacteria and fungi, The
carrier can be a solvent or dispersion medium containing, for
example, water, ethanol, polyol (for example, glycerol,
propylene glycol, and liquid polyetheylene glycol, and the
like), and suitable mixtures thereof The proper fluidity can
be maintained, for example, by the use of a coating such as
lecithin, by the maintenance of the required particle size in
the case of dispersion and by the use of surfactants, Prevention of the action of microorganisms can be achieved by
various antibacterial and antifingal agents, for example,
parabens, chlorobutanol, phenol, ascorbic acid, thimerosal,
and the like, In many cases, it will be preferable to include
isotonic agents, for example, sugars, polyalcohols such as
manito!, sorbitol, sodium chloride in the composition, Prolonged absorption of the injectable compositions can be
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brought about by including in the compositiOn an agent
which delays absorption, for example, aluminum monostearate and gelatin,
Sterile injectable solutions can be prepared by incorporating the active compound (e,g,, a fragment of a target
protein) in the required amount in an appropriate solvent
with one or a combination of ingredients enumerated above,
as required, followed by filtered sterilization, Generally,
dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those
enumerated above, In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred
methods of preparation are vacuum drying and freeze-drying
which yields a powder of the active ingredient plus any
additional desired ingredient from a previously sterile-filtered solution thereof
Oral compositions generally include an inert diluent or an
edible carrier, They can be enclosed in gelatin capsules or
compressed into tablets, For the purpose of oral therapeutic
administration, the active compound can be incorporated
with excipients and used in the form of tablets, troches, or
capsules, oral compositions can also be prepared using a
fluid carrier for use as a mouthwash, wherein the compound
in the fluid carrier is applied orally and swished and expectorated or swallowed, Pharmaceutically compatible binding
agents, and/or adjuvant materials can be included as part of
the composition, The tablets, pills, capsules, troches and the
like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline
cellulose, gum tragacanth or gelatin; an excipient such as
starch or lactose, a disintegrating agent such as alginic acid,
Primage!, or corn starch; a lubricant such as magnesium
stearate or Sterotes; a glidant such as colloidal silicon
dioxide; a sweetening agent such as sucrose or saccharin; or
a flavoring agent such as peppermint, methyl salicylate, or
orange flavoring,
For administration by inhalation, the compounds are
delivered in the form of an aerosol spray from pressured
container or dispenser which contains a suitable propellant,
e,g,, a gas such as carbon dioxide, or a nebulizer,
Systemic administration can also be by transmucosal or
transdermal means, For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation, Such penetrants are gen-
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erally known in the art, and include, for example, for
transmucosal administration, detergents, bile salts, and
fusidic acid derivatives. Transmucosal administration can be
accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds
are formulated into ointments, salves, gels, or creams as
generally known in the art.
The compounds can also be prepared in the form of
suppositories (e.g., with conventional suppository bases
such as cocoa butter and other glycerides) or retention
enemas for rectal delivery.
In one embodiment, the active compounds are prepared
with carriers that will protect the compound against rapid
elimination from the body, such as a controlled release
formulation, including implants and microencapsulated
delivery systems. Biodegradable, biocompatible polymers
can be used, such as ethylene vinyl acetate, polyanhydrides,
polyglycolic acid, collagen, polyorthoesters, and polylactic
acid. Methods for preparation of such formulations will be
apparent to those skilled in the art. The materials can also be
obtained commercially from Alza Corporation and Nova
Pharmaceuticals, Inc. Liposomal suspensions (including
liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to
methods known to those skilled in the art, for example, as
described in U.S. Pat. No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used
herein includes physically discrete units suited as unitary
dosages for the subject to be treated; each unit containing a
predetermined quantity of active compound calculated to
produce the desired therapeutic effect in association with the
required pharmaceutical carrier. The specification for the
dosage unit forms of the subject technology are dictated by
and directly dependent on the unique characteristics of the
active compound and the particular therapeutic effect to be
achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of
individuals.
Toxicity and therapeutic efficacy of the molecules of the
subject technology can be determined by standard pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD50 (the dose lethal to 50% of the
population) and the ED50 (the dose therapeutically effective
in 50% of the population). The dose ratio between toxic and
therapeutic effects is the therapeutic index and it can be
expressed as the ratio LD50/ED50. Compounds which
exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care
should be taken to design a delivery system that targets such
compounds to the site of affected tissue in order to minimize
potential damage to uninfected cells and, thereby, reduce
side effects.
The data obtained from the cell culture assays and animal
studies can be used in formulating a range of dosage for use
in humans. The dosage of such compounds lies preferably
within a range of circulating concentrations that include the
ED 50 with little or no toxicity. The dosage may vary within
this range depending upon the dosage form employed and
the route of administration utilized. For any compound used
in the method of the subject technology, the therapeutically
effective dose can be estimated initially from cell culture
assays. A dose may be formulated in animal models to
achieve a circulating plasma concentration range that
includes the IC50 (i.e., the concentration of the test com-

pound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be
used to more accurately determine useful doses in humans.
Levels in plasma may be measured, for example, by high
performance liquid chromatography.
The nucleic acid molecules of the subject technology can
be inserted into vectors and used as gene therapy vectors.
Gene therapy vectors can be delivered to a subject by, for
example, intravenous injection, local administration (see
U.S. Pat. No. 5,328,470) or by stereotactic injection (see
e.g., Chen eta!. (1994) Proc. Nat!. Acad. Sci. USA 91:30543057). The pharmaceutical preparation of the gene therapy
vector can include the gene therapy vector in an acceptable
diluent, or can comprise a slow release matrix in which the
gene delivery vehicle is imbedded. Alternatively, where the
complete gene delivery vector can be produced intact from
recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce
the gene delivery system.
The pharmaceutical compositions can be included in a
container, pack, or dispenser together with instructions for
administration.
VI. Methods of Treatment
The subject technology provides for both prophylactic
and therapeutic methods of treating Alzheimer's Disease
(AD), early-stage AD, elevated risk of AD, mild cognitive
impairment (MCI), or other forms of age-related cognitive
decline in a subject. In some embodiments, the subject
technology provides a method of treating Alzheimer's Disease (AD), early-stage AD, elevated risk of AD, mild
cognitive impairment (MCI), or other forms of age-related
cognitive decline in a subject in need thereof, comprising
administering to the subject a molecule that promotes calcium-release stabilization in ryanodine receptors (RyR) and/
or inosital triphosphate receptors (InsP3R) in brain cells.
In some other embodiments, the subject technology provides a method of treating Alzheimer's Disease (AD), earlystage AD, elevated risk of AD, mild cognitive impairment
(MCI), or other forms of age-related cognitive decline in a
subject in need thereof, comprising administering to the
subject a calcium (Ca 2 +)-release stabilizing molecule,
wherein said molecule induces reduction, inhibition or
reversal of Ca 2 + dysregulation in brain cells of the subject.
In an embodiment, the subject technology also provides
methods of preventing the development AD or other cognitive impairments associated with Ca2 + dysregulation in a
subject. These methods involve, for targets that are significantly decreased in expression or activity, the administration
of that target protein, or the introduction of mRNA or DNA
corresponding to the decreased target (e.g., by gene
therapy), to thereby increase the levels of the target protein
in the subject. In this manner, the development AD or other
cognitive impairments associated with Ca2 + dysregulation in
a subject can be prevented.
With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the
field of pharmacogenomics. "Pharmacogenomics", as used
herein, includes the application of genomics technologies
such as gene sequencing, statistical genetics, and gene
expression analysis to drugs in clinical development and on
the market. More specifically, the term refers the study of
how a subject's genes determine his or her response to a
drug (e.g., a subject's "drug response phenotype", or "drug
response genotype".) Thus, another aspect of the subject
technology provides methods for tailoring an individual's
prophylactic or therapeutic treatment with either the target
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molecules of the present subject technology or target modulators according to that individual's drug response genotype.
Pharmacogenomics allows a clinician or physician to target
prophylactic or therapeutic treatments to subjects who will
most benefit from the treatment and to avoid treatment of
subjects who will experience toxic drug-related side effects.
In one aspect, the subject technology provides a method
for preventing in a subject, a disease or condition (e.g., AD
or other cognitive impairments) associated with decreased
target expression or activity or associated with aberrant
target activity (e.g., calcium release dysregulation in RyRs
and/or InsP3Rs), by administering to the subject a molecule
or an agent which modulates target protein expression or at
least one target protein activity in a way that the course of
the Ca2 + -dysregulation associated with aging and/or AD
phenotype is stopped or reversed. Subjects at risk for a
disease which is caused or contributed to by decreased target
expression or activity can be identified by, for example, any
or a combination of diagnostic or prognostic assays as
described herein. Administration of a prophylactic agent can
occur prior to the manifestation of symptoms characteristic
of the differential target protein expression, such that a
disease or disorder is prevented or, alternatively, delayed in
its progression. Depending on the type of target aberrancy
(e.g., increase or decrease in expression level), for example,
a target protein, target protein agonist or target protein
antagonist agent can be used for treating the subject. The
appropriate agent can be determined based on screening
assays described herein. Examples of agents such as small
molecules or large molecules that modulate the target molecules (e.g., Ca2 + release-stabilizing molecules or Ca 2 +
channels including RyRs and InsP3Rs) of the subject technology can be immunosuppressants such as rapamycin, and
analogues of rapamycin, such as CCI-779 and analogue
described in U.S. Pat. No. 5,362,718, incorporated herein by
reference, FK506, macolides of FK506 and rapamycin (Dumont, F. et a!., "The Immunosuppressive Macrolides
FK-506 and Rapamycin Act as Reciprocal Antagonists in
Murine T Cells", J. Immunol. 144: 1418-1424 (1990),
synthetic anmalogues ofrapamycin, FK506 (R. S. Coleman
et a!., "Degradation and Manipulations of the Immunosuppressant FK506: Preparation of Potential Synthetic Intermediates," Heterocycles, 28, pp. 157-161 (1989) and U.S. Pat.
No. 6,200,985, each of which is hereby incorporated herein
by reference) or JTV519 (K201) a 1,4-benzothiazepine drug
with antiarrhythmic and cardioprotective properties (see
Diabetes, Metabolic Syndrome and Obesity: Targets and
Therapy 2012:5 89-99, which is hereby incorporated herein
by reference).
Alternatively, the examples of molecules that can be used
in the methods of the subject technology further include
non-immunosuppressive ligands. The non-immunosuppressive lingand of immunophilins, junctophilins, calmodulins
or calcium receptors of the subject technology can be a low
molecular weight, small molecule compound having an
affinity for the Ca2 + release-stabilizing molecules or Ca 2 +
receptors of the subject technology. For example, when the
compound binds to a Ca 2 + release-stabilizing molecule, it
can enhance its Ca2 + release-stabilizing activity. As its name
suggests, the non-immunosuppressive ligands or compounds are devoid of any significant immunosuppressive
activity. Examples of a non-immunosuppressive neurolmmunophilin FKBP ligands that may be used in the method
and pharmaceutical composition of the subject technology
are set forth, for example, in PCT Publication W000/09108,
which is hereby incorporated herein by reference.

Another aspect of the subject technology pertains to
methods of modulating the expression or activity of a target
protein (i.e., a Ca 2 + release-stabilizing molecule or a Ca 2 +
receptor of the subject technology) for therapeutic purposes.
Accordingly, in an exemplary embodiment, the modulatory
method of the subject technology involves contacting a cell
with a molecule or agent that modulates the expression or
activity of a target protein. A molecule or an agent that
modulates the expression or activity of a target protein can
be a nucleic acid or a protein, a naturally-occurring target
molecule of a target protein (e.g., a target protein substrate),
a target protein antibody, a target protein agonist or antagonist, a peptidomimetic of a target protein agonist or antagonist, or other small or large molecules. In one embodiment,
the molecule stimulates one or more target protein.
Examples of such stimulatory agents include active target
protein and a nucleic acid molecule encoding target protein
that has been introduced into the cell. In another embodiment, the molecule inhibits one or more target protein
activities. Examples of such inhibitory molecules include
antisense target protein nucleic acid molecules, anti-target
protein antibodies, and target protein inhibitors. These
modulatory methods can be performed in vitro (e.g., by
culturing the cell with the agent) or, alternatively, in vivo
(e.g., by administering the agent to a subject). As such, the
present subject technology provides methods of treating an
individual afflicted with a disease or disorder characterized
by aberrant expression or activity of a target protein or
nucleic acid molecule. In one embodiment, the method
involves administering a molecule or an agent (e.g., an agent
identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or corrects) target protein expression or activity. In another
embodiment, the method involves administering a target
protein or nucleic acid molecule as therapy to compensate
for reduced or aberrant target protein expression or activity.
Stimulation of target protein activity is desirable in situations in which target protein is abnormally downregulated
and/or in which increased target protein activity is likely to
have a beneficial effect. For example, stimulation of target
protein activity is desirable in situations in which a target is
downregulated and/or in which increased target protein
activity is likely to have a beneficial effect.
In another embodiment, the subject technology provides
a method of treating a subject afflicted with AD or other
cognitive impairments, including providing to cells of the
subject a protein with Ca2 + release-stabilizing activity, e.g.,
FKBP1 b. In a related embodiment, the protein is provided to
the cells by providing a vector including a polynucleotide
encoding the Ca 2 + release-stabilizing molecules, e.g.,
FKBP1b protein to the cells.
In another embodiment, the subject technology provides
a method of inhibiting AD or other cognitive impairments
associated with Ca2 + dysregulation in a subject at risk for
developing AD or other cognitive impairments, including
stimulating the activity (in case of protein) or expression (in
case of a gene) of a Ca 2 + release-stabilizing molecule, e.g.,
FKBP1b.
In another embodiment, the subject technology provides
a method of treating a subject afflicted with AD or other
cognitive impairments, including providing to cells of the
subject a molecule (e.g., a polynucleotide, a protein or a
small organic or large molecule) that can ligate to and
stabilize Ry receptor, InsP3 receptor, or a Ca 2 + releasestabilizing molecule, e.g., FKBP1 b, in said cells of the
subject. In a related embodiment, the molecule can enhance
the activity of the Ca 2 + release-stabilizing molecules in vivo.
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VII. Predictive Medicine
The present subject technology pertains to the field of
predictive medicine in which diagnostic assays and prognostic assays are used for prognostic (predictive) purposes to
thereby treat an individual prophylactically.
1. Diagnostic Assays
In some embodiments, the subject technology relates to
diagnostic assays for diagnosing Alzheimer's Disease (AD),
early-stage AD, elevated risk of AD or mild cognitive
impairment (MCI) in a patient, including obtaining a biological sample from the patient, detecting presence, quantity,
or level of expression of one or more calcium-release
stabilizing immunophilin, junctophilin and/or calmodulin
genes in the biological sample from said patient, wherein a
difference in the presence, quantity or level of expression of
said one or more genes in the sample as compared to a
control is indicative of Alzheimer's Disease (AD), earlystage AD, elevated risk of AD or mild cognitive impairment
(MCI).
An exemplary agent for detecting target protein is an
antibody capable of binding to target protein, preferably an
antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody,
or a fragment thereof (eg., Fab or F(ab') 2 ) can be used. The
term "labeled", with regard to the probe or antibody, is
intended to encompass direct labeling of the probe or
antibody by coupling (i.e., physically linking) a detectable
substance to the probe or antibody, as well as indirect
labeling of the probe or antibody by reactivity with another
reagent that is directly labeled. Examples of indirect labeling
include detection of a primary antibody using a fluorescently
labeled secondary antibody and end-labeling of a DNA
probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is
intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids
present within a subject. That is, the detection method of the
subject technology can be used to detect target mRNA,
protein, or genomic DNA in a biological sample in vitro as
well as in vivo. For example, in vitro techniques for detection of target mRNA include Northern hybridizations and in
situ hybridizations. In vitro techniques for detection of target
protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of target
genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of target protein
include introducing into a subject a labeled anti-target antibody. For example, the antibody can be labeled with a
radioactive target whose presence and location in a subject
can be detected by standard imaging techniques.
In one embodiment, the biological sample contains protein molecules from the patient or test subject. Alternatively,
the biological sample can contain mRNA molecules from
the test subject or genomic DNA molecules from the test
subject. A preferred biological sample is a serum sample
isolated by conventional means from a subject.
In another embodiment, the methods further involve
obtaining a control biological sample (e.g., non-AD or
samples showing no cognitive impairments associated with
Ca 2 + dysregulation) from a control subject, contacting the
control sample with a compound or agent capable of detecting target protein, mRNA, or genomic DNA, such that the
presence of target protein, mRNA or genomic DNA is
detected in the biological sample, and comparing the presence of target protein, mRNA or genomic DNA in the

control sample with the presence of target protein, mRNA or
genomic DNA in the test sample.
The subject technology includes methods that quantifY
expression levels in clinical samples as well as methods that
determine whether a gene of interest is expressed at all or
expressed above a threshold (e.g., a control threshold) in
clinical samples. Thus, an assay which provides a "yes or
no" result without necessarily providing quantification of
gene expression is within the scope of the subject technology. The subject technology may involve quantitative or
qualitative assessment of gene expression.
Various methods for detecting the level of expression of
one or more genes in a sample is known in the art. For
example, traditional Northern blotting, nuclease protection,
RT-PCR and differential display methods may be used for
detecting gene expression levels, including Taqman and flap
endonuclease assays. Additional assays include array or chip
hybridization-based methods, which are convenient when
determining the expression levels of a larger number of
genes.
In some embodiments, the subject technology may
employ reverse transcription polymerase chain reaction (RTPCR), which is a sensitive method for the detection of
mRNA, including low abundant mRNAs present in clinical
tissue samples. The application of fluorescence techniques
to RT-PCR combined with suitable instrumentation has led
to quantitative RT-PCR methods that combine amplification,
detection and quantification in a closed system. Two commonly used quantitative RT-PCR techniques are the Taqman
RT-PCR assay (ABI, Foster City, USA) and the Lightcycler
assay (Roche, USA).
In other embodiments, the subject technology employs
detection and quantification of RNA levels in real-time using
nucleic acid sequence based amplification (NASBA) combined with molecular beacon detection molecules. NASBA
is a singe-step isothermal RNA-specific amplification
method that amplifies mRNA in a double stranded DNA
environment, and this method has recently proven useful in
the detection of various mRNAs, and in the detection of both
viral and bacterial RNA in clinical samples.
In yet other embodiments, the subject technology uses an
assay employing a flap endonuclease, such as the Invader™
assay (Third Wave Technologies). In the case of using the
invader method, an invader probe containing a sequence
specific to the region 3' to a target site, and a primary probe
containing a sequence specific to the region 5' to the target
site of a template and an unrelated flap sequence, are
prepared. Cleavase is then allowed to act in the presence of
these probes, the target molecule, as well as a FRET probe
containing a sequence complementary to the flap sequence
and an auto-complementary sequence that is labeled with
both a fluorescent dye and a quencher. When the primary
probe hybridizes with the template, the 3' end of the invader
probe penetrates the target site, and this structure is cleaved
by the Cleavase resulting in dissociation of the flap. The flap
binds to the FRET probe and the fluorescent dye portion is
cleaved by the Cleavase resulting in emission of fluorescence.
In another embodiment, the subject technology employs
hybridization-based assays. Nucleic acid hybridization simply involves contacting a probe and target nucleic acid under
conditions where the probe and its complementary target can
form stable hybrid duplexes through complementary base
pairing (see Lockhart et a!., (1999) WO 99/32660). The
nucleic acids that do not form hybrid duplexes are then
washed away leaving the hybridized nucleic acids to be
detected, typically through detection of an attached detect-
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able label. It is generally recognized that nucleic acids are
denatured by increasing the temperature or decreasing the
salt concentration of the buffer containing the nucleic acids.
Under low stringency conditions (e.g., low temperature
and/or high salt) hybrid duplexes (e.g., DNA-DNA, RNARNA or RNA-DNA) will form even where the annealed
sequences are not perfectly complementary. Thus specificity
of hybridization is reduced at lower stringency. Conversely,
at higher stringency (e.g., higher temperature or lower salt)
successful hybridization requires fewer mismatches. One of
skill in the art will appreciate that hybridization conditions
may be selected to provide any degree of stringency. In a
preferred embodiment, hybridization is performed at low
stringency, in this case in 6xSSPE-T at 37° C. (0.005%
Triton x-100) to ensure hybridization and then subsequent
washes are performed at higher stringency (e.g., 1xSSPE-T
at 37° C.) to eliminate mismatched hybrid duplexes. Successive washes may be performed at increasingly higher
stringency (e.g., down to as low as 0.25xSSPET at 37° C. to
50° C.) until a desired level of hybridization specificity is
obtained. Stringency can also be increased by addition of
agents such as formamide. Hybridization specificity may be
evaluated by comparison of hybridization to the test probes
with hybridization to the various controls that can be present
(e.g., expression level control, normalization control, mismatch controls, etc.).
The hybridized nucleic acids are typically detected by
detecting one or more labels attached to the sample nucleic
acids. The labels may be incorporated by any of a number of
means well known to those of skill in the art (see Lockhart
eta!., (1999) WO 99/32660).
When employing hybridization formats, solution-based
and solid support-based assay formats may be employed.
Solid supports containing oligonucleotide probes for differentially expressed genes of the subject technology can be
filters, polyvinyl chloride dishes, silicon or glass based
chips, etc. Such wafers and hybridization methods are
widely available, for example, those disclosed by Beattie
(WO 95/11755). Any solid surface to which oligonucleotides can be bound, either directly or indirectly, either
covalently or non-covalently, can be used. An exemplary
solid support is a high density array or DNA chip. These
contain a particular oligonucleotide probe in a predetermined location on the array. Each predetermined location
may contain more than one molecule of the probe, but each
molecule within the predetermined location has an identical
sequence. Such predetermined locations are termed features.
There may be, for example, about 2, 10, 100, 1000 to
10,000; 100,000 or 400,000 of such features on a single solid
support. The solid support, or the area within which the
probes are attached may be on the order of a square
centimeter.
Oligonucleotide probe arrays for expression monitoring
can be made and used according to any techniques known in
the art (see for example, Lockhart eta!., (1996) Nat. Biotechno!. 14, 1675-1680; McGall et a!., (1996) Proc. Nat.
Acad. Sci. USA 93, 13555-13460). Such probe arrays may
contain at least two or more oligonucleotides that are
complementary to or hybridize to two or more of the genes
described herein. Such arrays may also contain oligonucleotides that are complementary or hybridize to at least about
2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, or all of the genes
described herein as being differentially expressed in AD.
Probes based on the sequences of the genes described
herein may be prepared by any commonly available method.
Oligonucleotide probes for assaying the tissue or cell sample
are preferably of sufficient length to specifically hybridize

only to appropriate, complementary genes or transcripts.
Typically the oligonucleotide probes will be at least 10, 12,
14, 16, 18, 20 or 25 nucleotides in length. In some cases
longer probes of at least 30, 40, or 50 nucleotides will be
desirable.
As used herein, oligonucleotide sequences that are
complementary to one or more of the genes described
herein, refers to oligonucleotides that are capable of hybridizing under stringent conditions to at least part of the
nucleotide sequence of said genes. Such hybridizable oligonucleotides will typically exhibit at least about 75%
sequence identity at the nucleotide level to said genes,
preferably about 80% or 85% sequence identity or more
preferably about 90% or 95% or more sequence identity to
said genes. In some embodiments, the oligonucleotide
probes are identical to a portion of the genes disclosed
herein, and usually identical in a range of 10-30 nucleotides,
such as 15-20 nucleotides.
Further, with respect to arrays, one of skill in the art will
appreciate that an enormous number of array designs are
suitable for the practice of the subject technology, where
array embodiments are desirable. The array will typically
include a number of probes that specifically hybridize to the
sequences of interest. See WO 99/32660 for methods of
producing probes for a given gene or genes. In addition, in
a preferred embodiment, the array will include one or more
control probes.
High density array chips of the subject technology include
"test probes." Test probes may be oligonucleotides that
range from about 5 to about 500 or about 5 to about 50
nucleotides, more preferably from about 10 to about 40
nucleotides and most preferably from about 15 to about 40
nucleotides in length. In other particularly preferred embodiments the probes are about 20 to 25 nucleotides in length. In
another preferred embodiment, test probes are double or
single strand DNA sequences. DNA sequences are isolated
or cloned from natural sources or amplified from natural
sources using natural nucleic acid as templates. These
probes have sequences complementary to particular subsequences of the genes whose expression they are designed to
detect. Thus, the test probes are capable of specifically
hybridizing to the target nucleic acid they are to detect.
In addition to test probes that bind the target nucleic
acid(s) of interest, the high density array can contain a
number of control probes. The control probes fall into three
categories referred to herein as (1) normalization controls;
(2) expression level controls; and (3) mismatch controls.
Normalization controls are oligonucleotide or other
nucleic acid probes that are complementary to labeled
reference oligonucleotides or other nucleic acid sequences
that are added to the nucleic acid sample. The signals
obtained from the normalization controls after hybridization
provide a control for variations in hybridization conditions,
label intensity, "reading" efficiency and other factors that
may cause the signal of a perfect hybridization to vary
between arrays. In a preferred embodiment, signals (e.g.,
fluorescence intensity) read from all other probes in the
array are divided by the signal (e.g., fluorescence intensity)
from the control probes thereby normalizing the measurements. Other methods for normalizing gene expression data
are known in the art, such as those described, for example,
in W02001/020043 or US 20060136145, each of which is
hereby incorporated herein by reference.
Virtually any probe may serve as a normalization control.
However, it is recognized that hybridization efficiency varies
with base composition and probe length. Preferred normalization probes are selected to reflect the average length of the
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other probes present in the array, however, they can be
selected to cover a range of lengths. The normalization
control( s) can also be selected to reflect the (average) base
composition of the other probes in the array, however in a
preferred embodiment, only one or a few probes are used
and they are selected such that they hybridize well (i.e., no
secondary structure) and do not match any target -specific
probes.
Expression level controls are probes that hybridize specifically with constitutively expressed genes in the biological sample. Virtually any constitutively expressed gene
provides a suitable target for expression level controls.
Typical expression level control probes have sequences
complementary to subsequences of constitutively expressed
"housekeeping genes" including, but not limited to the
beta-actin gene, the transferrin receptor gene, the GAPDH
gene, the HPRTl gene, and the like. Alternatively or in
addition, the expression level controls can be obtained from
genes whose expressions are known not to change with AD.
Mismatch controls may also be provided for the probes to
the target genes, for expression level controls or for normalization controls. Mismatch controls are oligonucleotide
probes or other nucleic acid probes identical to their corresponding test or control probes except for the presence of
one or more mismatched bases. A mismatched base is a base
selected so that it is not complementary to the corresponding
base in the target sequence to which the probe would
otherwise specifically hybridize. One or more mismatches
are selected such that under appropriate hybridization conditions (e.g., stringent conditions) the test or control probe
would be expected to hybridize with its target sequence, but
the mismatch probe would not hybridize (or would hybridize
to a significantly lesser extent). Preferred mismatch probes
contain a central mismatch. Thus, for example, where a
probe is a twenty-mer, a corresponding mismatch probe will
have the identical sequence except for a single base mismatch (e.g., substituting a G, a C or a T for an A) at any of
positions 6 through 14 (the central mismatch).
Mismatch probes thus provide a control for non-specific
binding or cross hybridization to a nucleic acid in the sample
other than the target to which the probe is directed. Mismatch probes also indicate whether a hybridization is specific or not. For example, if the target is present the perfect
match probes should be consistently brighter than the mismatch probes. In addition, if all central mismatches are
present, the mismatch probes can be used to detect a
mutation. The difference in intensity between the perfect
match and the mismatch probe (IBM)-I(MM)) provides a
good measure of the concentration of the hybridized material.
In certain embodiments, the obtained expression profile of
a biological sample from a subject at risk of AD is compared
to a single reference profile (e.g., that of an individual
known not to have AD or that of a universal control sample
obtained from healthy individuals) to obtain information
regarding the phenotype (e.g., positive or negative test of
early-stage AD) of the sample being assayed. In yet other
embodiments, the obtained expression profile is compared to
two or more different reference profiles (e.g., that of individuals known not to have AD or that of two or more
universal control samples from healthy individuals) to
obtain more in depth information regarding the phenotype of
the assayed sample. For example, the obtained expression
profile may be compared to a positive and negative reference
profile to obtain confirmed information regarding whether
the sample has the phenotype of interest (e.g., indications for
early-stage AD or being at risk of developing AD).

The comparison of the obtained expression profile and the
one or more reference profiles may be performed using any
convenient methodology, where a variety of methodologies
are known to those of skill in the array art, e.g., by
comparing digital images of the expression profiles, by
comparing databases of expression data, etc. Patents
describing ways of comparing expression profiles include,
but are not limited to, U.S. Pat. Nos. 6,308,170 and 6,228,
575, the disclosures of which are herein incorporated by
reference. Methods of comparing expression profiles are
also described above. Patent documents describing various
methods or algorithms for obtaining gene expression profiles
include, but are not limited to, US20030165952;
US20110236903A1;
US2011 0165566A1;
US2011 0098195A1;
US2011 007 6685A1;
US20100167939A1;
US20100112710A1;
US20090233297 A1;
US20090186348A1;
US20080171323A1; the disclosures of each of which is
hereby incorporated herein by reference. Other methods for
analyzing microarray data are well-known in the art including coupled two-way clustering analysis, clustering algorithms (hierarchical clustering, self-organizing maps) and
support vector machines. See, e.g., Eisen et a!., 95 PROC.
NATL. ACAD. SCI. USA 14863-68 (1998); Ermolaeva eta!,
20 NATURE GENET. 19-23 (1998); Tamayo et a!., 96
PROC. NATL. ACAD. SCI. USA 2907-12 (1999); Getz et
a!., 97 PROC. NATL. ACAD. SCI. USA 12079-84 (2000);
Brown et a!., 97 PROC. NATL. ACAD. SCI. USA 262-67
(2000); and Holter et a!., 97 PROC. NATL. ACAD. SCI.
USA 8409-14 (2000).
The comparison step results in information regarding how
similar or dissimilar the obtained expression profile is to the
one or more reference profiles, which similarity information
is employed to determine the phenotype of the sample being
assayed. For example, similarity with a positive control
indicates that the assayed sample has a responsive phenotype similar to the responsive reference sample. Likewise,
similarity with a negative control indicates that the assayed
sample has a non-responsive phenotype to the non-responsive reference sample.
The level of expression of a biomarker (e.g., FKBP1a,
FKBP1b, junctophilin 3, junctophilin 4, calmodulin 3, a
functional fragment thereof, or a variant thereof) can be
further compared to different reference expression levels.
For example, a reference expression level can be a predetermined standard reference level of expression in order to
evaluate if expression of a biomarker or biomarker set is
informative and make an assessment for determining
whether the patient tests positive or negative for AD or risk
of developing AD. Additionally, determining the level of
expression of a biomarker can be compared to an internal
reference marker level of expression which is measured at
the same time as the biomarker in order to make an assessment for determining whether the patient tests positive or
negative for AD or risk of developing AD. For example,
expression of a distinct marker panel which is not comprised
of biomarkers of the subject technology, but which is known
to demonstrate a constant expression level can be assessed
as an internal reference marker level, and the level of the
biomarker expression is determined as compared to the
reference. In an alternative example, expression of the
selected biomarkers in a tissue sample which is a non-AD
sample can be assessed as an internal reference marker level.
The level of expression of a biomarker may be determined
as having increased expression in certain aspects. The level
of expression of a biomarker may be determined as having
decreased expression in other aspects. The level of expres-
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sian may be determined as no informative change in expression as compared to a reference level. In still other aspects,
the level of expression is determined against a pre-determined standard expression level as determined by the methods provided in, for example, W02012037378, which is
hereby incorporated herein by reference.
The subject technology also encompasses kits for detecting the presence of target in a biological sample. For
example, the kit can comprise a labeled compound or agent
capable of detecting target protein or mRNA in a biological
sample; means for determining the amount of target in the
sample; and means for comparing the amount of target in the
sample with a standard. The compound or agent can be
packaged in a suitable container. The kit can further comprise instructions for using the kit to detect target protein or
nucleic acid.
2. Prognostic Assays
The assays described herein, such as the preceding diagnostic assays, can be utilized to identify a subject having or
at risk of developing AD, MCI or other cognitive impairments. Furthermore, the prognostic assays can be used to
determine whether a subject can be administered an agent
(e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate)
to treat a disease or disorder associated with AD, MCI or
other cognitive impairments. For example, such methods
can be used to determine whether a subject can be effectively
treated with an agent for a disorder such as AD or other
cognitive impairments. Thus, the present subject technology
provides methods for determining whether a subject can be
effectively treated with an agent for a disorder associated
with increased or decreased target expression or activity in
which a test sample is obtained and target protein or nucleic
acid expression or activity is detected (e.g., wherein the
abundance of target protein or nucleic acid expression or
activity is diagnostic for a subject that can be administered
the agent to treat a disorder associated with increased or
decreased target expression or activity).
This subject technology is further illustrated by the following examples which should not be construed as limiting.
The contents of all references, patents and published patent
applications cited throughout this application, are incorporated herein by reference.

physiology or microarray analysis. Measures included levels
of RNA associated with Ca 2 + dyshomeostasis, quantification
ofFkbplb, calcium channel and RyR2 protein levels, intracellular measures of the post-burst AHP, accommodation
and intracellular Ca 2 + dynamics. control AAV (AAV titer,
3.56E12 GC) or received no treatment.
Three to 4 weeks after injection, intracellular recordings
of the slow after hyperpolarization (sAHP) were obtained
from CAl pyramidal neurons in acute hippocampal slices
from both ipsilateral and contralateral sides of nine Fkbpl binjected animals. Subsequently, qPCR of Fkbplb was performed on tissue from the dorsal tips and one slice each from
both hippocampi of eight of the nine animals studied electrophysiologically. In addition, brains of two other animals
unilaterally injected in hippocampus with AAV bearing the
Fkbplb were prepared for immunohistochemical studies.
Microinjection protocol. Under isoflurane anesthesia, rats
were placed in a David Kopf Instruments stereotaxic frame.
Small holes were drilled in the skull either unilaterally or
bilaterally (at points from bregma: posterior, 4.5 mm; lateral,
3.0 mm), and the dura was pierced to allow for microinjection. A Hamilton micro syringe was lowered 1.6 mm into the
dorsal hippocampus, a region critical for spatial memory. At
the target injection site (CAl stratum oriens at the peak of
the curve of stratum pyramidale), 2 fll of AAV-containing
vehicle was delivered at a rate of0.2 fll/min using a Stoelting
QSI microinjection pump. After injection, the syringe was
left in place for 5 min, then the small holes in the skull were
filled with bone wax, and the incision was sutured. Two to
4 weeks after unilateral microinjections of AAV, rats were
killed, and the brains prepared for sectioning and microscopy. See also, Gant eta!., 2011.
qPCR. For mRNA quantification, one-step real-time
reverse transcription (RT)-PCR was used. RT-PCR amplification was performed as described previously (Chen eta!.,
2000) using an ABI prism 7700 sequence detection system
(Applied Biosystems) and TaqMan One Step RT-PCR
reagents (Applied Biosystems ). All samples were run in
duplicate in a final volume of 50 fll containing 50-100 ng of
cellular RNA and a Taq-Man probe (200 f.LM) and primers
(300 nM each) with an amplicon spanning the rat Fkbplb
eDNA region from nucleotides 155 to 259. Cycling parameters for all assays were as follows: 30 min at 48° C., 10 min
at 95° C. followed by 40 cycles of 15 sat 95° C., and 1 min
at 60° C. Primers were designed using Primer Express
software (version 1.5; Applied Biosystems) and chemically
synthesized by Applied Biosystems (forward primer,
5'-GCAAGCAGGAAGTCATCAAAGG-3' SEQ ID N0.1;
reverse primer, 5'-CAGTAGCTCCATATGCCACATCA-3'
SEQ ID N0.2; TaqMan probe, 5'-AGCTCATCTGGGCAGCGCCTTCTT-3' SEQ ID N0.3). The RNA levels of
glyceraldehyde-3-phosphate dehydrogenase were used as
normalization controls for RNA quantification.
Patch-clamp recording ofCa2 + channel current in cultured
neurons. Whole-cell recordings of pharmacologically isolated Ca2 + channel currents, using Ba 2 + as the charge carrier,
were obtained from neurons in primary hippocampal cell
cultures at 9-12 DW, as described previously (Porter eta!.,
1997; Blalock eta!., 1999; Breweret a!., 2001; Norris eta!.,
2002). electrophysiological data were acquired at 5-20 kHz
using a patch-clamp amplifier (Axopatch 200A), DigiData
1320 digital input/output board and pClamp 7 (Molecular
Devices). Cell capacitance measures, membrane resistance,
access resistance, and holding current were obtained from
the membrane properties function in pClamp7. All cells
were held at +70 m V unless stated otherwise. Currentvoltage (I-V) relationships were determined by stepping the
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Example 1
AAV-mediated expression of the Fkbpl b open
reading frame (ORF) can counteract Ca2 +
dyshomeostasis and altered gene expression in the
hippocampus of aging rats
Methods and Materials
Subjects. Studies on adult animals used 3- to 4-month-old
male Fischer 344 rats obtained from Harlan. All protocols
and procedures were performed in accordance with institutional guidelines and were approved by the Animal Care and
Use Committee.
FKBPl b over expression in vivo with adena-associated
virus vectors. To achieve selective expression in vivo, an
adena-associated virus (AAV) vector was used to express
Fkbplb mRNA in vivo. Aged (22 mo) F344 rats received
unilateral or bilateral injections of 2 fll of AAV bearing the
Fkbpl b construct at a rate of 0.2 fll/min. Following 2-3
weeks of recovery the rats were sacrificed and tissue was
utilized for qPCR, immunohistochemistry, slice electro-
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voltage in increments of 10 m V from 70 to +60 m V for 150
ms. Current was averaged over five traces for each measurement point, and current density was determined by
dividing current by cell membrane capacitance (picoamperes per picofarad).
Current-clamp intracellular recording in hippocampal
slice pyramidal neurons. Young-adult male F344 rats were
anesthetized in a C02 chamber before rapid decapitation.
Our sharp-electrode electrophysiological methods have been
described previously (Thibault et a!., 2001; Gant et a!.,
2006). Briefly, intracellular recordings were obtained from
CAl pyramidal neurons in hippocampal slices (350-+mthick) maintained in oxygenated ACSF (in mM: 128 NaCI,
1.25 KH2P04, 10 glucose, 26 NaHC03, 3 KCI, 2 CaCI2,
and 2 MgCI2), using sharp glass pipettes filled with HEPES
(10 mM), KMeS04 (2M), and Calcium Orange tetrapotassium salt (5 mM; Invitrogen). Electrophysiological data
were acquired and analyzed using pC!amp 8, a sharpelectrode amplifier (Axoclamp 2B), and a DigiData 1320
board (Molecular Devices). Voltage records were digitized
at 2-20kHz and low-pass-filtered at 1 kHz. Input resistance
and AHP measures were obtained in current-clamp mode.
AHP duration and sAHP amplitude were measured after four
Na+ APs triggered by an intracellular depolarizing pulse.
The 5 mM concentration of Ca 2 + indicator used is in a range
commonly used in slice imaging experiments (Jaffe et a!.,
1992; Brown and Jaffe, 1994; Jaffe and Brown, 1994) and
apparently does not distort AHP waveforms or obscure aging
differences in the AHP (Thibault et a!., 2001; Gant et a!.,
2006).
Ca 2 + imaging. Methods used were similar to those
described previously by several groups (Miyakawa et a!.,
1992; Brown and Jaffe, 1994; Jaffe and Brown, 1994; Magee
and Johnston, 1995; Thibault eta!., 2001; Gant eta!., 2006).
Individual CAl neurons impaled with sharp pipettes and
loaded with the Ca 2 + indicator Calcium Orange were imaged
on the stage of a Nikon E600 microscope equipped with a 40
water immersion objective and a CCD camera (Roper Scientific/Princeton Instruments). Calcium Orange was allowed
to diffuse into the cell for at least 10 min before Ca 2 +
fluorescence measures were performed. Calcium Orange
was excited using a wavelength switcher (Sutter Instruments
Lambda DG-4) and software control (Axon Imaging Workbench; version 2.2.1.54; Molecular Devices). The 575 nm
wavelength was monitored through a dichroic mirror centered at 570 nm during excitation with the 550 nm wavelength. The intracellular Ca 2 + response was elicited by 10 s
of 7 Hz repetitive synaptic stimulation (RSS) delivered to
the Schaffer collaterals via bipolar stimulation electrode.
Stimulation intensity was set at AP threshold and generated
an action potential on essentially each pulse (Thibault et a!.,
2001 ). Ca 2 + responses were measured in a region of interest
corresponding to the visible outline of the cell soma, excluding surrounding low-intensity diffracted light. Although the
central region of the neuron appears brighter (see FIG. 6,
inset), this may be related in part to greater indicator loading
in this thicker central region of the cell (Tsien, 1988;
Nicotera et a!., 1994 ). After background subtraction from an
area devoid of cells adjacent to the recorded cell, percentage
change in fluorescence was determined relative to baseline
(% F/F). Optical sampling rate averaged +5 Hz, which
appeared sufficiently sensitive to detect significant changes
in the Ca2 + response. Excitation of Calcium Orange was
essentially continuous during a 10 strain ofRSS, but control
runs showed that bleaching was minimal (+0.21 +0.09% at 5
s RSS; +0.69+0.35% at 10 s RSS; n+ 7 cells). The ryanodinesensitive component (CICR component) of the Ca 2 +

response was determined by subtracting the post-ryanodine
Ca 2 + response from the pre-ryanodine response [(pre-ryanodine% llF/F)-(post-ryanodine% llF/F)=ryanodine sensitive
component].
Statistical analyses. Data analysis was performed with
Clampfit8(Molecular Devices), and statistical analysis was
performed with Stat-View (SAS Institute). Variables were
analyzed using ANOVA across all groups with means and
SEs reported. Fisher's protected least significant difference
(PLSD) test was used for post hoc group comparisons. p
values +0.05 were considered significant.
This microinjection results in overexpression of FKBPl b
mRNA and protein (confirmed by qPCR and immunohistochemistry). The electrophysiological effects of unilateral
microinjection into one hippocampus of aging rats of adenaassociated viral (AAV) vector containing the open reading
frame (ORF) of the Fkbpl b gene is shown in FIG. 1. The
quantitative group measures (mean+/-SEM) of intracellular
electrode recordings of membrane voltage responses that are
well-established to vary in magnitude with the amount of
calcium released by intracellular ryanodine receptors (see
Gant eta!, 2006). As shown in FIG. 1, the voltage responses
obtained in this study are the amplitude of the calciumdependent medium afterhyperpolarization (mAHP)(top
panel), amplitude of the calcium-dependent slow afterhyperpolarization (sAHP)(middle panel), and duration of the
calcium-dependent slow afterhyperpolarization (sAHP)
(bottom panel). The data reveal significant differences in
these responses in neurons recorded from the viral vectorinjected hippocampus vs. those recorded from the control
(non-injected) hippocampus, such that the injected-side neurons exhibit a younger phenotype (lesser magnitude). Larger
amplitude AHPs develop with aging and have been correlated with impaired memory.
These results show that the AAV microinjections impact
several biotargets of aging rats, indicating that calcium
release-stabilizing molecules such as FKBPs are novel
therapeutic agents and/or targets for interventions aimed at
protection against unhealthy brain aging or Alzheimer's
disease.
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FKBPlb Overexpression and Reversal of Aging
Biomarkers
The aim of this study was to determine whether AAVmediated overexpression of the Fkbp 1b open reading frame
(ORF) can reverse hippocampal Ca 2 + dyshomeostasis and
cognitive impairment in aging rats. Aged (22 mo) F344 rats
received unilateral or bilateral injections of 2 fll of AAV
bearing the Fkbplb ORF construct or empty AAV vector
control. IHC and qPCR analyses revealed substantial
upregulated FKBPl b in hippocampal sites of AAV-ORF
injection. See FIG. 3.
Following 4-5 weeks, the rats were tested on a spatial
water maze, after which hippocampal tissue was utilized for
slice electrophysiology, and qPCR, immunohistochemistry
or microarray analysis. Results showed that the AAV-ORF
microinjections reversed electrophysiological and behavioral biomarkers of aging in rats. More importantly, it was
determined that overexpression of FKBPl b in hippocampus
of aged rats improved memory and maze learning. See FIG.
4. These results show that calcium release-stabilizing molecules such as FKBPs can be used as therapeutic agents for
treatment of age-related cognitive malfunctions.
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Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the subject
technology described herein. Such equivalents are intended
to be encompassed by the following claims. The results
indicate that

of other forms without departing from the spirit thereof. The
accompanying claims and their equivalents are intended to
cover such forms or modifications as would fall within the
scope and spirit of the subject technology. The contents of all
references, patents and published patent applications cited
throughout this application, are incorporated herein by reference.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 3
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 1
gcaagcagga agtcatcaaa gg

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 2
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 2
23

cagtagctcc atatgccaca tea

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
probe

<400> SEQUENCE, 3
agctcatctg ggcagcgcct tctt

The foregoing description is provided to enable a person
skilled in the art to practice the various embodiments
described herein. While the subject technology has been
particularly described with reference to the various figures
and configurations, it should be understood that these are for
illustration purposes only and should not be taken as limiting
the scope of the subject technology.
Furthermore, to the extent that the term "include," "have,"
or the like is used in the description or the claims, such term
is intended to be inclusive in a manner similar to the term
"comprise" as "comprise" is interpreted when employed as
a transitional word in a claim.
The word "exemplary" is used herein to mean "serving as
an example, instance, or illustration." Any embodiment
described herein as "exemplary" is not necessarily to be
construed as preferred or advantageous over other embodiments.
While certain aspects and embodiments of the subject
technology have been described, these have been presented
by way of example only, and are not intended to limit the
scope of the subject technology. Indeed, the novel methods
and systems described herein may be embodied in a variety
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What is claimed is:
1. A method of treating Alzheimer's Disease (AD), earlystage AD, mild cognitive impairment (MCI), or other forms
of age-related cognitive decline in a subject in need thereof,
comprising administering to the subject by way of injection
or infusion into brain tissue that is affected by AD, earlystage AD, MCI or age-related cognitive decline, a replication-defective viral expression vector comprising a polynucleotide sequence that encodes at least one ofFKBPla or
FKBPlb, or a polynucleotide having at least about 60%
sequence identity over its entire length to at least one of
FKBPla, FKBPl b, or both and encoding a polypeptide
having calcium release inhibiting activity on ryanodine
receptors (RyRs ), said polynucleotide sequence being operably linked to a promoter sequence, wherein expression of
the at least one of FKBPla or FKBPl b, or the polynucleotide having at least about 60% sequence identity over its
entire length to at least one of FKBPla, FKBPlb, or both,
in the brain tissue of the subject results in reduced calciumrelease from RyRs in the brain tissue of the subject and
reduces cognitive impairment of the subject.
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2. The method of claim 1, wherein the replication-defec-

tive viral expression vector is an adena-associated expression vector.
3. The method of claim 1, wherein the replication-defective viral expression vector comprises a polynucleotide
encoding FKBPl b.
4. The method of claim 1 wherein the polynucleotide
encodes FKBPla.
5. The method of claim 2 wherein the replication-defective viral expression vector is injected or infused into the
hippocampus of the subject.
6. A method of treating Alzheimer's Disease (AD), earlystage AD, mild cognitive impairment (MCI), or other forms
of age-related cognitive decline in a subject in need thereof,
comprising administering to the subject by way of injection
or infusion into brain tissue that is affected by AD, earlystage AD, MCI or age-related cognitive decline, a replication-defective viral expression vector comprising a polynucleotide sequence that encodes at least one of FKBPla or
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FKBPlb, said polynucleotide sequence being operably
linked to a promoter sequence, wherein expression of the
FKBPla, FKBPl b , or both in the brain tissue of the subject
results in reduced calcium-release from ryanodine receptors
in the brain tissue of the subject and reduces cognitive
impairment of the subject.
7. The method of claim 6, wherein the replication-defective viral expression vector is an adena-associated expression vector.
8. The method of claim 6, wherein the replication-defective viral expression vector comprises a polynucleotide
encoding FKBPl b.
9. The method of claim 6 wherein the polynucleotide
encodes FKBPla.
10. The method of claim 6 wherein the replicationdefective viral expression vector is injected or infused into
the hippocampus of the subject.
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